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Abstract 
The increased level of FABP5 promotes tumourigenicity and metastasis partially by 
suppressing apoptosis of prostate cancer cells. Recent studies demonstrated that in 
castration-resistant prostate cancer cells, androgen-receptor related signaling pathway 
did not effectively affect the malignant progression, whereas FABP5-PPARγ-VEGF 
signaling axis had a dominant influence in promoting the malignant 
progression. Therefore, targeting FABP5 with its inhibitors to promote apoptosis 
could be a novel strategy for prostate cancer treatment. In this work, we first treated 
an androgen-responsive cell line 22Rv1 and a highly malignant androgen-independent 
cell line PC3 with a chemically synthesized FABP5 inhibitor SB-FI-26 and a bio-
FABP5-inhibitor dmrFABP5, respectively, to prove their promoting effect on 
apoptosis of the cancer cells; then we investigated the molecular mechanisms 
involved in how FABP5 inhibitor promoted apoptosis. Results showed that SB-FI-26 
produced significant increases in percentages of apoptotic cells in both 22Rv1 and 
PC3 by 18.80% (±4.08) and 4.60% (±1.13), respectively. DmrFABP5 produced 
significant increases in percentages of apoptotic cells by 23.13% (±2.41) and 15.76% 
(±3.01), respectively, in these two cell lines. Both FABP5 inhibitors significantly 
reduced the levels of the phosphorylated (presumably, biologically active form) 
nuclear fatty acid receptor PPARγ, indicating that these inhibitors promoted apoptosis 
of the cancer cells through suppressing the biological activity of PPARγ. Further 
studies showed that, as the reduction of the level of p-PPARγ, the levels of AKT and 
NFκB were coordinately altered. These changes eventually led to the increased levels 
of cleaved Caspase-9 and cleaved Caspase-3 and thus increased number of apoptotic 
cells. These results, together with some previous studies, suggested that FABP5 
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inhibitors promoted apoptosis in prostate cancer cells by suppressing the biological 
effect of FABP5, and FBAP5 may suppress apoptosis through increasing the 
biological activity of PPARγ, which, in turn, leads to a reduced apoptosis by 
interfering with the AKT and NFκB signaling pathway.  
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1. Introduction 
1.1 Epidemiology of cancer 
1.1.1 Cancer incidence 
Cancer has been and still is a serious worldwide health threat. According to the fifth 
version of GLOBOCAN, more than 14.1 million new cancer cases were diagnosed in 
the world in 2012 (7.4 million in men and 6.7 million in women) (1). Amongst all the 
male and female cancer cases, breast (15%), prostate (13%), lung (13%), and bowel 
(12%) cancers are most common types (2) (Fig 1.1). 
 
   
Figure 1.1. Twenty Most Common Cancers in the UK in 2015 (Cancer Research UK, 
2015). 
When cancer cases are grouped according to ages of the patients, the highest number 
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of cases is found in the 84 to 90 years old patient group. The number of cases 
diagnosed in the group aged up to 24 year old accounted for only 1.1% of the total 
cancer patients. However the number of cases diagnosed in the group aged at or over 
65  accounted for more than 65% of the total cancer cases (2) (Fig 1.2 ). While the 
black and white males have higher rates of cancer cases than Asian males,  cancer 
incidence is more common in white females than that in Asian and black females (3).  
 
Figure 1.2.  The number of cancer registrations and the age-specific rates (per 
100,000 people) in the UK in 2015 (2).   
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1.2 Epidemiology of prostate cancer 
 
1.2.1 Prostate cancer incidence 
Prostate cancer is the most common cancer type in men and the second most common 
cancer in western countries (1) (4). Recently, incidence rates of prostate carcinoma 
raised were increased for all nations. Prostate cancer incidences are high in North 
America, Australia, France and Sweden, medium in Denmark, England, Italy, Spain 
and Israel; and low in Singapore, Japan, India, and China, respectively (5, 6). Around 
417,000 additional prostate cancer patients were diagnosed each year in Europe (7); 
and also in the UK, it is common in male with the highest incidence rate, which is the 
17
th
 amongst the European countries (6). About 47,700 additional cases were 
diagnosed in the UK every year from 2013-2015. In recent ten years, prostate cancer 
incidence rate has increased by approximate 6% in males in the UK, this number is 
expected to increase by 12% between 2014 and 2035 (4). 
 
Age is closely related to prostate cancer incidence. Older men have a higher incidence 
rate.  In the UK, more than 35% additional prostate cancer cases were diagnosed in 
men aged 75 or over during the period of 2013-2015 (4). Age-specific incidence rate 
raised from around 50-54, reached the peak in 75-79, and slightly dropped from 80-84 
before it increased steadily again. The highest rate was in 90 or over (8) (Fig 1.3). 
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Figure 1.3. Average Number of prostate cancer new cases per year and age-specific 
incidence rates per 100,000 Population in males, UK, 2013-2015 (8) 
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1.2.2 Prostate cancer mortality 
Prostate cancer is the 5
th
 most common cause of cancer death for men in the world. 
The number raised more rapidly in developing countries including part of South 
America, Asia, sub-Sahara Africa and the Caribbean than in developed countries (1, 5, 
6). In Europe, prostate cancer is the 6
th
 most common cause of cancer death and the 
number of death in the UK ranked the 15th amongst the European countries (7). 
In the UK, prostate cancer is the 2nd most common cause of cancer death. In 2016, 
about 11,600 (13%) deaths was caused by prostate cancer in the UK (9). Prostate 
cancer mortality was linked with the increased age (8, 9).  Between 2014 and 2016, 
around 74% of prostate cancer death occurred in men aged 75 or over in the UK. Age-
specific mortality rate started to raise from as low as age 55-59 to the highest rate in 
men aged 90 or more (9) (Fig 1.4). 
 
Figure 1.4. The average number of prostate cancer deaths each year and age specific 
mortality rates in Males in the UK in 2014-2016 (9). 
 
 




1.2.3 Prostate cancer survival 
Prostate cancer surviving rate increased between 1970 and 2012. In 1970s, around 2 
in 10 men survived for a decade after their prostate cancer diagnosis. In 2012, more 
than 8 in 10 men survived. The increased survival rate may be caused by the 
development of prostate-specific antigen (PSA) test and transurethral resection of the 
prostate (TURP) which can provide better and earlier stage diagnosis (10, 11). Five-
year survival rate of patients showed a relationship with age. Survival rates raised 
from 91% in men aged 15-49 and reached the peak at 94% in men aged 60-69, then 
rapidly fell to the bottom of 66% in men aged 80-99 diagnosed with prostate cancer in 
the UK during 2009 to 2013 (9) (Fig 1.5).  
                         
 
Figure 1.5. Prostate cancer relative ten-year survival rates in England (9). 
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1.2.4 Risk factors of prostate cancer 
 
1.2.4.1 Age 
Prostate cancer is rarely diagnosed in men before 40-year old, the incidence rises 
rapidly with the increasing age (5). The incidences were 13.7% for the age group of 
60-79 year old, 2.2% for the age group of 40-59 year old and lower than 0.005% in 
the group younger than 39 years old (12). In addition, the rate of prostate cancer 
discovered during autopsies in deceased people was much higher: around 20% 
between the age of 50 and 60 and raised to 50% between 70 and 80 in men (13). 
 
1.2.4.2 Race 
It was reported that prostate cancer incidence and mortality rate are different amongst 
different races (14). People who had the highest prostate cancer risk were African 
American men, which had 275.3 prostate cases per 100,000 men; whereas  whites had 
a rate of only 172.9 in 100,000, a reduction of 37.2% (15).  Asian men had the lowest 
risk of prostate cancer, although it was reported that Asian men had a rapidly 
increasing trend in recent years (16).  
 
1.2.4.3 Family history 
It was recognized that family history was one of the key risk factors in men for 
prostate cancer (17). Men who have diagnosed prostate cancer family history are 
expected to have prostate cancer diagnosed 6 years earlier than those without family 
history (18). Hereditary factors were estimated in 5-10% of diagnosed cases, 40% 
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amongst those diagnosed patients were below the age of 55. Therefore, there was a 
strong relationship between family prostate cancer history and personal prostate 
cancer risk in men (19). Nevertheless, the clinical presentation of this disease with 
family history did not indicate cancer presenting at an early age, and there was no 
evidence to show any differences in the degree of malignancies between the 
hereditary-related cases and other cases (20-22). In addition, it was suggested that if 
one or more members of a family had a history with breast cancer,  other family male 
members would have a significantly higher risk to develop prostate cancer (23). 
 
1.2.4.4 Diet and lifestyle 
It is reported that proper dietary habits and healthy lifestyle may be benefit for 
suppressing the risk of prostate cancer (24, 25). Men with high level consumption of 
fat and red meat has been proved to be associated with higher prostate cancer risk, 
whereas men with high level consumption of fatty fish represent lower risk (25, 26) In 
western countries, people consume high omega-6 polyunsaturated fatty acids (PUFA), 
whereas people in Asian countries with their high consumption of food containing a 
relatively high level of omega-3 PUFA, vegetables, complex carbohydrates, lean 
meats, and antioxidants have lower incidences of prostate cancer (27). The difference 
in diet between western countries and Asian countries may provide some clues into 
the relationship between fat level consumption and prostate cancer (28). Some factors, 
including circulating insulin-like growth factor 1 (IGF-1) and omega-6 PUFA family 
member linoleic acid (LA) were proved to be associated with increasing prostate 
cancer risk (24, 29, 30). Nevertheless, high-level intake of eicosapentaenoic acid 
(EPA), an omega-3 polyunsaturated fatty acid, is related to a declined risk of 
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prostate cancer (30).  
 
1.2.4.5 Other factors 
The statistical data showed that some factors, such as cigarette smoking, alcohol 
consumption, socioeconomic status, occupation, vasectomy, prostate gland 
inflammation and sexually transmitted infection, may have a link to the risk of 
prostate cancer  (31).  
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1.3 The pathology of prostate cancer 
1.3.1 Anatomy of the prostate gland 
Prostate, as the largest male genital accessory gland, located at the neck of the urinary 




Figure 1.6: Schematic illustration of Male Reproductive system. (33) 
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The human prostate is divided to three zones: a peripheral zone, a central zone and a 
transitional zone (32). The peripheral zone is the largest zone of the prostate, it 
consists of approximately 70% of the total volume of the gland (32). The central zone 
makes up 25% of the total gland volume (32). The transitional zone makes up 5% of 
the total prostate tissue mass (Fig 1.7) (32). In these three zones, the peripheral zone is 
the most common location of  inflammation and prostate tumour (64%) (34); the 
central zone accounts only 2.5% of prostate cancer occurrence (35); the transitional 





Figure 1.7. Anterior oblique view of the prostate and the urethra (37). The urethra 
originates proximally from the urinary bladder and follows a course distally through 
the prostate. The prostate is divided into three zones: central zone (CZ), transition 
zone (TZ) and peripheral zone (PZ). The ejaculatory ducts and seminal vesicles are 
situated at prostate base. The anterior fibromuscular stroma (AFS) is located 
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anteriorly. 
1.3.2 Physiology of prostate 
Prostate, known as a male sex accessory organ, plays a major role in reproductive 
process. Prostate gland produces a fluid that, together with sperm cells and fluids 
produced by the seminal vesicle, bulbourethral gland and other glands, makes up to 
semen. The fluid produced by prostate contains fructose, glucose, enzymes and PSA, 
and functions as diet for sperm to go through the female body during the reproduction 
process. Prostate fluid contains acidic minerals such as zinc and citrate, but other fluid 
in semen produced by seminal vesicles are alkaline which can neutralize the acidic 
vaginal secretions to help sperm surviving  (38, 39) 
 
1.3.3 Normal prostate cells 
Prostate gland consists of epithelial and stromal cells. The prostate epithelial cells can 
be further divided into three main subtypes: luminal cells, basal cells and 
neuroendocrine cells (40).  
Luminal cells are the most common type amongst prostate epithelial cells. They are 
part of the exocrine compartment of prostate, secreting protein such as PSA and 
prostatic acid phosphate (PAP) to the glandular lumina (41). Luminal cells are 
androgen depended cells, which express a high level of androgen receptor (AR). They 
also express cytokeratin  (CK) 8, CK18 and the cell surface marker CD 57 (42). 
Basal cells are the second largest epithelial cells in prostate gland. They are located 
above the basement membrane and are relatively undifferentiated with a limited 
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secretory ability. It is believed that basal cells form the main compartment of 
proliferation in prostate gland. Basal cells are androgen independent cells and they are 
unlikely to express AR and thus they do not response to androgen ablation treatment 
(43). These cells express high levels of CK 5 and 14 as well as CD44. In addition, 
they also express autocrine factors such as BCL-2  and p63 which have a protective 
function against DNA damage (44). 
Neuroendocrine cells are located between the luminal and basal cells in prostate gland. 
They are not responsible to androgen and can be identified by expressing serotonin, a 
thyroid stimulating hormone, and chromogranin A. The clear function of 
neuroendocrine cells are not fully investigated, however, there are evidences suggest 
that they may support proliferation of luminal cells and development to the advanced 
stage of prostate carcinoma (45, 46). 
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1.3.4 Benign prostate hyperplasia and prostate cancer initiation 
1.3.4.1 Benign prostate hyperplasia (BPH) 
BPH is known as an enlargement in size of the gland, which is non-malignant and is 
widely observed in aged men. This phenomenon is diagnosed by over growth of the 
cellular elements of prostate and linked to age in almost all males (50% men with 
BPH are around age 60 and 90% men with BPH are by age 85). BPH is not caused by 
cancer or a precursor for cancer (47-49). BPH usually can be observed in prostate 
transition zone, a ring of tissue around the urethra and its growth is toward the centre 
side, constantly tightening around the urethra and are associated with lower urinary 
tract symptoms (LUTS) (50).  
It is suggested that androgen plays a key role in BPH progress. Blockade of androgen 
or AR signaling path way is a major therapeutic method for BPH (50-52). However, 
the certain molecular mechanisms of how AR signaling affect BPH is still not fully 
investigated. 
 
1.3.4.2 Prostatic intraepithelial neoplasia (PIN) 
Prostatic Intraepithelial Neoplasia (PIN) is known as a sub stage, or  a cancer 
precursor, of cellular transformation from a normal condition to a malignant prostatic 
epithelium. PIN indicates unusual proliferation of epithelial cells without invasion 
into surrounding stroma (53). PIN can be identified by a variety of architectural and 
cytological aspects so that it has minimal differences which could lead to 
indistinguishable from cancer (54).  
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PIN can be classified into low grade and high grade. Low grade PIN is a highly 
differentiated early invasive tumour with a major composition of basal cells (55). 
High grade PIN represents a poorly differentiated tumour with a secretory luminal cell 
population (43, 56). Four main forms of high grade PIN have been classified: Tufting 
(the most common type),  cribriform, micropapillary and flat (57). It is shown that 
high grade PIN is an important marker and the only identified precursor of the 
prostatic carcinoma (58). 
1.3.4.3 Gleason grading system 
Dr. David Gleason established a histological grading method (Gleason score, GS) to 
evaluate the aggressiveness of prostate cancer in 1966 (59). The Gleason grade ranges 
from 1 – 5. It is a prostate cancer assessment system, which depends on subjective 
microscopic determination, represents the degree of loss of normal glandular tissue 
architecture. For example,  grade 1 is the least aggressive pattern and Grade 5 is the 
most aggressive pattern  (59) (Figure 1.8). 
Because of the histological variation of different lesions within each tumour, two 
grades (primary and secondary) were recorded in each case. They can range from 2-
10 by adding the two grade patterns together to form the so call Gleason scores (GS) 
or the combined GS (60). GS is a sum of primary grade, larger than 50% of total 
pattern seen, which shows the majority of tumour; and secondary grade, observed 
between 5% and 50% of total pattern, which shows the minority of tumour. This 
system has classified the scores into three groups: well differentiated (GS<6), 
moderately differentiated  (GS 6-7) and poorly differentiated  (GS 8-10) (61-63).  
 




Figure 1.8. Gleason score grading system (61). Grade 1, well-differentiated and slight 
anaplasia. Grade 2, moderately-differentiated and moderate anaplasia. Grade 3-4 
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1.3.5 Diagnosis and treatment of prostate cancer 
Most prostate cancer diagnosis decisions are firstly on the basis of elevated serum 
prostatic specific antigen (PSA) or digital rectal examination (DRE). Abnormal DRE 
is an indication for biopsy, however, the independent variable PSA is a better bio-
marker of cancer than either DRE or transrectal ultrasound (TRUS). Definitive 
diagnosis depends on histopathologic grading (64). However, each procedure has its 
limitations leading to an over-biopsy for diagnosis, an over-treatment of low-risk 
patients and non-essential surgery (65).  
In localized stage of prostate cancer, radical prostatectomy and external radiation are 
the common treatments (66).Since the recognition of the growth of prostate cancer 
cells depends on the presence of androgen, Androgen deprivation therapy (ADT) has 
been the main treatment for patients diagnosed with locally advanced and metastatic 
prostate cancer (67). The methods of ADT were classified as surgical castration 
(orchiectomy), chemical castration and anti-androgen therapy (68). The surgical 
castration consists of removing the testicles of the patient, The drugs used in chemical 
castration are LHRH agonists or antagonists, including leuprorelin, goserelin, 
triptorelin, histrlin, huserelin and degarelix (69, 70). Anti-androgens compete with 
endogenous androgens from binding with the ligand binding poket of AR. There are 
two general classes of anti-androgen therapy, steroidal (RU-486, cyproterone acetate, 
etc.) and non-steroidal (Flutamide, bicalutamide and Bicalutamide) (71).  
However, patients with ADT frequently become resistance to castration. In this stage, 
prostate cancer developed to androgen-independent prostate cancer, or Castration-
Resistant Prostate Cancer (CRPC). CRPC is the result of regrowth of prostate cancer 
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cells that have adapted to non-androgen or low-androgen environment. Recently, 
many studies reported the molecular mechanisms, such as AR-dependent and AR-
independent pathways , influenced the CRPC development, but the clear mechanisms 
in this progression in still not fully understood (72, 73). 
 
1.4 Prostate cancer cell lines 
Prostate cancer researchers developed several cell models to help investigating the 
molecular pathogenesis, proliferation, apoptosis, tumorigenicity and metastasis. The 
most common prostate cancer cell lines widely used in laboratories are: PNT2, 
LNCaP, 22Rv1, DU-145, PC3 and PC3-M. 
1.4.1 PNT2 
PNT2 cell line is a normal human prostate cell line which was established from a 33 
years old male’s prostate epithelial cells by immortalization using transfection with a 
plasmid containing simian virus 40 genome (SV40) with a defective replication origin 
(74). Successful immortalisation was achieved only with SV40 expressing both 
large T and small t oncogenes, while attempts to immortalise with a vector 
expressing SV40 large T alone have given a few strains showing no extended 
lifespan and no cells which overcame the crisis (74).PNT2 cells also express PSA 
and PAP but negative with CK 14 ( a marker of epithelial basal cells) (75).  
1.4.2 LNCaP 
LNCaP cells were obtained from a needle aspiration biopsy of a lymph node 
metastatic lesion of a 50 years old male with prostate adenocarcinoma in 1977 (76). 
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LNCaP cells are androgen sensitive, they express a high affinity nuclear androgen 
receptor (mutant T877A) which up-regulate cell growth by responding to androgens. 
In vivo studies showed that tumours occurred at the point of injection and were 
informed earlier in male than in female mice, indicating a probable androgen-sensitive 
characteristic. LNCaP cells express CK8 and 18, and express a wild type TP53 (77).   
1.4.3 22Rv1 
22Rv1 cell is derived from a human prostatic cancer xenograft (spread in mice after 
castration induced regression and relapse of the parental, androgen-responsible 
CWR22 xenograft) (78). 22Rv1 cell line is an androgen-sensitive, moderately 
malignant prostate epithelial cell line. This cell line express high level of PSA and AR, 
and has unique genotype and phenotype comparing to  other prostate cell lines (78, 
79). 
1.4.4 DU-145 
DU-145 was the first well established prostate cancer cell line. It was isolated from a 
moderately-differentiated brain metastasis of a 69 years old Caucasian male (76). DU-
145 cell express extremely low level of PAP and negative with AR and PSA 
expression (76). They also express intermediate filament proteins and CK 7, 8, 9 and 
19, but not CK 5 and 14 (80, 81). In vivo studies showed when DU-145 inoculated 
into SCID mice, metastases were found in liver, lung, spleen, adrenals, kidneys and 
lymph nodes (80). 
1.4.5 PC3 and PC3-M 
PC3 cell was isolated from a bone marrow metastasis of a GS 4 prostatic 
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adenocarcinoma from a 62 years old male (82). PC3 cells are androgen-independent 
and negative with PSA and AR expression. PC3-M is a metastatic subline of PC3. It 
was obtained from liver metastasis produced in nude mice by intra splenic injection of 
PC3 cells and it has similar properties with PC3 but with higher malignancy and more 
aggressive (83). 
1.5 Androgens and prostate cancer 
 
1.5.1 Androgens and prostate 
Male androgens, also named as testoids, have a key impact on controlling the 
development, growth, function of prostate gland and on the maintenance of male 
characteristics by binding to AR (84). The main androgen in men is testosterone 
(more than 90%) which is primarily synthesized by the testes. Androgen is essential to 
the development of  the basic function of prostate (85). The secretion of androgen in 
men is controlled by hypothalamus. As the androgen level (mainly testosterone) in 
peripheral blood is reduced, a pulse of luteinizing Hormone Releasing Hormone 
(LHRH) will be issued from hypothalamus and this pulse of LHRH can bind to the 
specific receptor in the pituitary gland, which triggers the release of luteinizing 
hormone (LH) (85). The released LH in peripheral blood leads to progress of 
steroidogenesis in leydig cells (86). Testosterone transformed to a more potent 
metabolite form: dihydrotestosterone (DHT) under the stimulation of 5-α-reductase 
enzyme in prostate gland. DHT binds to AR, a ligand controlling transcription factor 
in  the nuclear hormone super family. In nucleus, DHT-AR bind to and activate 
androgen response elements (AREs) in promoter regions of downstream genes which 
could regulate cell growth, survival and differentiation of prostate cells (85-92).   
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In prostate cancer, in the localized stage radical prostatectomy and external radiation 
treatment are common therapeutic methods (66). For patients diagnosed as advanced 
or metastatic prostate cancer, suppression of androgen signaling is a key method for 
treatment, therefore  androgen deprivation therapy (ADT) by medical, surgical 
castration, anti-androgens and combined androgen blockade becomes a common 
therapy (93). As the primarily effective treatment, ADT is able to induce primary 
response in 80% - 90% patients. Nevertheless, after 14 – 20 months, the duration of 
ADT response ends and patients experience progression to androgen-independent 
prostate cancer, which is no longer in response to androgen deprivation (94).  
 
1.5.2 Androgen-independent prostate cancer 
Androgen-independent prostate cancer, was also known as Castration Resistant 
Prostate Cancer (CRPC) (86). CRPC is a castration-insensitive stage of prostate 
cancer which has a worse prognosis and a shorter survival time from the beginning of 
progression (86). The identification of molecular mechanisms involved in the 
translation of prostate cancer cells from androgen-dependent to androgen-independent 
is a main issue for the prostate cancer research field and is one of the most important 
issues or prerequisite for the development of novel CRPC therapeutic strategy (73, 95, 
96). 
1.6 Progression to castration-resistance prostate cancer 
The molecular mechanism on how androgen-dependent prostate cancer progresses to 
CRPC is an important research subject and it was investigated by many different 
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laboratories. Currently, ADT is the main therapy for prostate cancer (67). 
Nevertheless, most of the cases treated with ADT will relapse and progress to CRPC. 
Some CRPC cells express AR, some CRPC cells do not express AR. Whereas the AR-
negative CRPC cells generally do not respond to ADT treatment,   AR-positive CRPC 
cells are largely androgen responsive and express AR. But their further development 
and expansion does not depend on androgen stimulation anymore and thus ADT 
treatment is no longer effective to CRPC (73, 97). How exactly the prostate cancer 
cells become CRPC cells from androgen-dependent cells is not fully understood. 
There were several theories were brought about to explain the mechanism in this 
important transition (72). Every theory can only explain part of the question; and 
currently there is no single hypothesis can completely explain this transition 
satisfactorily.  
1.6.1 AR-dependent signaling pathway in CRPC 
AR is a member of the steroid hormone receptor family of ligand-dependent 
transcription factor. It consists of several functional domains: (1) ligand-binding 
domain (LBD); (2) DNA-binding domain (DBD); (3) hinge region; (4) large N-
terminal domain (NTD) (98). It has been reported that a significant mechanism in 
CRPC growth is the continuous activation of AR (99). Although the ADT reduces the 
androgen level in peripheral blood, but it does not affect the DHT level. Thus the 
stimulation to AR can be continued by DHT (100). It was suggested that several 
molecular and cellular modifications may be linked to the development of CRPC, 
including AR amplifications, AR mutations, AR-ligand signaling, aberrant AR co-
regulating factors and the AR splice- Biomarkers in prostate cancer (101, 102). 
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1.6.2 Other pathways 
Many studies reported additional pathways related to CRPC progression. These 
including: inhibition of apoptosis by activation of anti-apoptotic BCL-2 gene which 
can lead to androgen independence (103, 104); it was reported that PI3K/AKT or 
mitogen activated protein kinase (MAPK) pathway can be stimulated by the 
activation of receptor tyrosine kinases and further causes phosphorylation of AR, 
which lead to produce a ligand independent AR (105, 106). Multiple pathways 
involve in prostate cancer cells survival in reduced level of androgens. Apart from the 
main theory that supported the AR sensitivity-amplification opinion, some new 
hypotheses were proposed in the recent years. One of the most important novel 
hypotheses was the FABP5-related signaling pathway theory, which suggested that it 
was this pathway, rather than the AR-related pathway, that played a key role in 
promoting the malignant progression of the CRPC cells (107). 
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1.7 Fatty acid binding proteins 
1.7.1 Fatty acid binding protein family 
Fatty acids are produced by hydrolysis of ester linkage in oil or fat, and have 
complicated functions on varies aspects of the cell metabolism in human body. Fatty 
acids functions as an energy source in cells (108). Recent study also demonstrated that 
fatty acids are signaling molecules and play important roles in intracellular signaling 
transduction in such cell metabolic processes as cell proliferation, gene regulation, 
and apoptosis (109-111). The most common major fatty acids in plant and animal are 
linoleic acids and arachidonic acids. Also, eicosapentaenoic acid (EPA) and 
docosahexaenoic acid (DHA) are considered to be major fatty acids in fish oil  (112). 
Fatty acids are easy to penetrate cell membrane and get into cytoplasm after they are 
produced by adipocytes. Free fatty acids can also move to other cells either by passive 
diffusion or by transporters. After Fatty acids have entered into cytoplasm, they can 
either join metabolic pathways and serve as sources of nutrition or bind to 
intracellular fatty acid-binding proteins, which take them to different organelles (111). 
Fatty acid binding proteins (FABPs), also known as intracellular lipid chaperones, 
belong to the super lipid-binding protein (LBP) family (113). Twelve members of 
FABPs have been identified since 1972, but 2 of them are restricted to fish (114, 115). 
FABP family members were first known or commonly located in different organs and 
were named after those organs (Table 1.1). However, the expression of FABPs is not 
limited to the named organs or cells. For example, FABP1 (liver FABP) expressed 
mainly in liver, and also in other organs or tissues like pancreas, intestine, lung, 
stomach, and kidney; FABP5 (epidermal FABP) is highly expressed in skin, tongue, 
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adipocyte, brain, intestine, macrophage, kidney, liver, lung, mammary gland, heart, 
skeletal muscle, testis, retina, lens and spleen (109, 115). Wherever fatty acids are 
expressed, they act as common materials for lipid biosynthesis and storage. Increased 
amount of FABP synthesis is usually accompanied by the increasing influx of fatty 
acids into the cells (116). 
                Table 1.1 Fatty acid-binding protein multigene family (117). 




FABP1  Liver FABP  L-FABP  Liver, intestine, 
pancreas, kidney, 
lung, stomach  
FABP2  Intestinal FABP  I-FABP  Intestine, liver  
FABP3  Heart/muscle 
FABP  








adipose tissue  
FABP4  Adipocyte FABP  A-FABP  Adipocyte, 
macrophage, 
dendritic cell  









spleen, prostate  
FABP6  Ileal FABP  Il-FABP  Ileum, ovary, 
adrenal gland, 
stomach  
FABP7  Brain FABP  B-FABP  Brain, glia cell, 
retina, mammary 
gland  
FABP8  Myelin FABP  M-FABP  Peripheral 
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nervous system  
FABP9  Testis FABP  T-FABP  Testis, salivary 
gland, mammary 
gland  
Fabp10  Liver FABP  L-FABP  Liver of teleost 
fish  
Fabp11  –  –  Liver, intestine, 
muscle, brain, 
heart, eye, swim 
bladder, gills, 
kidney, skin, 
ovary and testis 
of teleost fish  
FABP12  –  –  Retinoblastoma 
cell from human. 
Retina, testicular 
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1.7.2 General functions of FABPs 
FABPs had come up with many features. As a lipid chaperone, FABPs can actively 
bind and transport lipids to specific locations or organelles of the cells. These 
locations or organelles include lipid droplets for lipid storage and endoplasmic 
reticulum for signal transduction, transport and membrane synthesis (118). Fatty acids 
can be transported to different destinations inside the cells: to the mitochondria or 
peroxisomal for oxidation; to cytosolic or other enzymes for regulating enzymes’ 
activity; to the nucleus for lipid mediated transcriptional regulation (118). Fatty acids 
can also be transported to the extracellular signaling through an autocrine or paracrine 
mechanism  (119) (Figure 1.9). 
Furthermore, FABP can enter the nucleus and transfer fatty acids to transcriptional 
regulators, for example, allowing the peroxisome proliferator-activated receptors 
(PPARs) family to perform its biological functions (120-122). There is evidence that 
FABPs transfers fatty acids from the cytoplasm to their receptor PPAR in the nucleus 
(118). In addition, it has been reported that FABP expression in cancer tissues is 
located in the cytoplasm and nucleus (121, 123). These investigations suggested that 
FABPs involve in specific signaling pathways in the nucleus to control gene 
expression. The process of fatty acid-transportation and the their route of  metabolism 
inside the cell are illustrated in Figure 1.9. 
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Figure 1.9. Putative functions of FABPs in the cell. FABPs have been put forward to 
play a role in the transport of lipids tospecific compartments in the cell by passive 
diffusion or by transporters (e.g. CD36): to lipid droplets for storage; to the 
endoplasmicreticulum for signalling, trafficking and membrane synthesis; to the 
mitochondria orperoxisome for oxidation; to cytosolic or other enzymes to regulate 
their activity; to the nucleus for the control of lipid-mediated transcriptional 
programs via nuclear hormone receptors (NHRs) (109). 
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1.7.3 The Structure of FABPs  
The FABP structure had been studied by X-ray crystallography, nuclear magnetic 
resonance and other biochemical methods. FABPs showed a range of 15% to 70% 
amino acid sequence homology (113). However, highly similar tertiary structures 
were found amongst FABPs (124). Generally, FABP has a 10-strand antiparallel β-
barrel structure. The binding pocket is located in the β-barrel, and one side of binding 
pocket is consist of an N-terminal helix-loop-helix motif, which is supposed to be the 
main location to bind to fatty acids (113). It has been shown that all FABPs have a 
three-element fingerprints (Figure 1.10). 
  
 




Figure 1.10. Fingerprint for fatty acid binding proteins (109). 
 
All FABPs bind long-chain fatty acids and have ligand selectivity due to small 
structural differences between isoforms (124). Except for unsaturated fatty acids, the 
more hydrophobic the ligands are, the higher their binding affinity is (125). The need 
for target cells may also determine the affinity and selectivity of major isotypes that 
exist at different sites (113). For example, FABP7 is highly selective for very long-
chain fatty acids such as docosahexaenoic acid (125). On the other hand, FABP1 have 
the binding capacity of a wide range of ligands from lysophospholipids to haem (126). 
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1.8 FABP5 (or cutanious fatty acid binding protein) in prostate cancer 
FABP5 is a member of FABP family and a 15kDa cytosolic protein that binds with 
high affinity to long and middle chain fatty acids (127). It has been identified that 
FABP5 widely expresses in the endothelial cells of the placenta, heart, skeletal muscle, 
small intestine, renal medulla and in the goblet cells of the lung (128). Previous 
studies indicated that FABP5 level was extremely high in prostate cancer cells (129, 
130). Moreover, FABP5, when  highly expressed,  can induce in vivo metastasis by 
promoting the expression of vascular endothelial growth factor (VEGF) (131-133). 
FABP5 has been proved to be a potential prognostic marker to predict the prognosis 
of patients and the target of therapeutic intervention (129, 134). FABP5 inhibition by 
siRNA can effectively inhibit prostate cancer in nude mice (131). It has been 
demonstrated that FABP5's tumour-promoting activity on prostate cancer cells 
depends on its binding and transporting capability with fatty acids, those fatty acids 
act as signaling molecules to activate its nuclear receptor PPARγ in CRPC cells (107). 
In addition, it was confirmed that the high expression of cytoplasmic FABP5 was 
significantly correlated with increasing nuclear PPARγ, and the increased levels of 
these two proteins were correlated with a lower survival rate of patients (123). 
Previously, it was demonstrated that fatty acids can activate PPARγ to trigger FABP5-
PPARγ-VEGF signaling pathway, which is novel target for therapeutic intervention or 
angiogenesis inhibition (135) (Figure 1.10). The FABP5-PPARγ-VEGF- signaling 
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Figure 1.11. Schematic illustrations of FABP5-PPARγ-VEGF pathway  (135). 
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1.9 FABP5 and apoptosis in prostate cancer 
The effect of FABP5 on apoptosis of prostate cancer cells has been detected in 
prostate cancer cells. Previous research showed that  the increased level of FABP5 
promoted tumorigenicity and metastasis of the prostate cancer cells and it may do so 
partially by reducing the apoptotic cell number or reducing the  response-sensitivity to 
apoptotic induction signals in prostate cancer cells (107).  Some studies also showed 
that FABP5 had a high influence in suppressing apoptosis in highly malignant DU145 
and PC3-M cells; probably by up-regulating some pro-apoptotic factors (136, 137). 
Furthermore, strong evidence showed that activation of PPARγ pathway inhibited 
cellular apoptosis in several types of cancers including prostate cancer (138-144). 
Despite all these previous studies, the true molecular mechanism involved in how 
FABP5 suppresses apoptosis of the cancer cells and how the FABP5-PPARγ pathway 
is related to apoptosis in prostate cancer are not known. 
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1.10 Targeting FABP5 in prostate cancer 
To investigate the possibility of targeting FABP5 as a therapeutic strategy for  prostate 
cancer treatment, the gene coding for FABP5 was knocked down by RNA interference 
in the highly malignant PC3-M cells to generate a subline (Si-clone-2) expressing 
significantly-reduced level of FABP5 (129). When othotopically implanted into 
mouse prostate gland and compared with the control, Si-clone-2 produced 63- fold 
reduction in average tumour size; 7- fold reduction in tumour incidence and 100% 
reduction in metastasis (129). This result showed that the short FABP5 siRNA 
generated from inside the cancer cells is very effective on suppressing the malignant 
progression of the cancer developed in mouse. However, due to the instability and the 
short life in body temperature, siRNA molecules will be degraded quickly soon after 
administrated as externally reagents. Thus, siRNA is not a proper treatment drugs for 
prostate cancer.  Even when the siRNA against FABP5 was dissolved in a stabilizing 
agent (named Atolecollagen, made from cow skin extracts) and was applied directly 
into the established prostate cancer tumour in nude mouse, these siRNA molecules 
could only slow and stabilize the tumour growth,  but could not reverse the malignant 
progression or reduce tumour sizes (134). Thus, in order to develop an ideal prostate 
cancer therapy by suppressing the biological activity of FABP5, discovery of highly 
effective, specific, and relatively stable novel FABP5 inhibitors is the key issue.  
We have recent found an effective FABP5 inhibitor, named SB-FI-26, which was an 
active component of a Chinese herbal medicine (Incarvillea sinensis) used to reduce 
pain and to treat rheumatism (145, 146). Our study showed that SB-FI-26 
significantly suppressed the proliferation, migration, invasiveness and colony 
formation of PC3-M cells in vitro. This inhibitor also suppressed both the metastases 
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and the primary tumours developed from cancer cells implanted orthotopically into 
the prostate glands of nude mice (147).  
The normal biological function of FABP5 is to bind to and to transport fatty acids into 
cells from different extracellular and intracellular sources (148). FABP5 binds to fatty 
acids with its carboxylate group through a fatty acid-binding motif that consists of 3 






) (148). Previous study revealed that tumor 
promotion effect of FABP5 in prostate cancer cells depended completely on the 
structural integrity of fatty acid binding motifs. We tested the possibility of getting an 
inhibitor of the wild type FABP5 by mutating the fatty acid-binding motif structure. 









) of the fatty acid-binding motif (107, 
149) to obtain a cDNA coding for a doubly-mutated FABP5; its recombinant product 
was named dmrFABP5.  While wild-type recombinant FABP5 (wtrFABP5) has full 
ability of binding to fatty acids and significantly promote tumorigenicity of prostate 
cancer cells by 13 times, dmrFABP5 cannot bind to fatty acids and cannot promote 
tumorigenicity (107). Our previous results showed that changing 2 of the 3 key amino 
acids in the fatty acid-binding motif in FABP5 has almost completely deprived of its 
fatty acid-binding ability (107). DmrFABP5, almost incapable of binding to fatty 
acids has not only lost its tumour-promoting activity, but also has gained an ability to 
suppress the biological activity of wtrFABP5, and thus is a novel FABP5 inhibitor. 
Surprisingly, when used as an therapeutic agent to treat prostate cancer developed in 
nude mouse,  dmrFABP5 produced more than 14-fold reduction in primary tumour 
mass and 100% inhibition in metastasis (150). The effect achieved by dmrFABP5 the 
therapeutic test in nude mouse model is much better than that obtained with SB-FI-26. 
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Thus dmrFABP5 is an excellent potential candidate compound for prostate cancer 
treatment.  
 
1.11 Apoptosis related pathways 
Apoptosis, or programmed cell death, is a fundamental mechanism with a key role 
throughout development. Apoptosis works through two main, alternative pathways: 
death receptor-mediated (or extrinsic) pathway and mitochondria-dependent (or 
intrinsic) pathway (151). The former pathway is initiated by ligation of specific death 
receptors by their ligands. The latter pathway, which was mainly studied in this work, 
triggered by mitochondrial outer membranepermeabilization (MOMP), which is 
partly influenced by BCL-2 family members bound to the mitochondrial membrane, 
including BAX and BCL-2, which are, respectively, pro- or anti-apoptotic regulatory 
proteins (151). The anti-apoptotic proteins BCL-2 inhibit the release of cytochrome C, 
whereas pro-apoptotic proteins (BAX, BAK, and BID) promote its release from 
mitochondria (152). Cytochrome C, along with Apaf-1 and dATP, form the 
“apoptosome” – a multiprotein complex that activates caspase-9 to initiate the 
caspase-3-dependent proteolytic cascade, which is considered a key executioner 
pathway of apoptotic cell death (153).  
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Figure 1.12. Two main pathways related to cell apoptosis: death receptor-mediated 
(or extrinsic) and mitochondria-dependent (or intrinsic). Extrinsic pathway is initiated 
by ligation of specific death receptors by their ligands. The main death receptors—Fas 
and tumour necrosis factor- (TNF-) related apoptosis inducing ligand (TRAIL) 
receptors DR4 and DR5—induce cell death following ligation with Fas ligand (FasL) 
or TRAIL, respectively, followed by recruitment of procaspase 8. The intrinsic 
pathway induces apoptosis by directly activating caspase 3 or by cleaving BID, 
resulting in mitochondrial dysfunction and subsequent release of cytochrome C and 
activation of caspases 9 and 3. Caspase 3 promotes the typical apoptosis features, 
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including DNA fragmentation and cell death. The intrinsic pathway is partly 
influenced by BCL family members bound to the mitochondrial membrane, including 
BAX (pro-apoptotic regulatory protein) and BCL-2 (anti-apoptotic regulatory protein) 
These proteins have opposite effect in affecting cytochrome C release from 
mitochondria. Cytochrome C and deoxyadenosine triphosphate (dATP) bind to 
apoptotic protease activating factor (APAF-1) to form a multimeric complex that 
recruits and activates procaspase 9, an apoptosis-mediating executioner protease that 
in turn activates caspase 3, resulting in cell apoptosis (154). 
1.12 Research Scope 
Based on previous investigations, it is reasonable to hypothesize that FABP5 and the 
fatty acids transported by FABP5 are important pharmacological target. Modulating 
FABP5 biological activity may provide changes on apoptosis in prostate cancer cells 
through PPARγ, AKT, NFκB and intrinsic apoptosis pathways. 
1.13 Research plan 
 
  
Detecting the effect of FABP5 inhibitors on prostate cancer cell apoptosis 
Assessing the promoting effect of FABP5 and inhibitory effect of FABP5 
inhibitor dmrFABP5 on PPARγ activation in prostate cancer cells 
Investigating the pathways involved in apoptosis-suppressing effect of 
FABP5 and apoptosis-promoting effect of dmrFABP5 in PC3 cells. 
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2. Materials and Methods 
2.1 Preparation of competent bacterial cells 
The E. coli (DH5α) glycerol was selected and seeded onto an LB-agar plate and the 
plate was incubated at 37
o
C overnight. On the following day, a single colony was 
inoculated into a conical flask containing 10mls LB broth at 37
o
C overnight with 
shaking at 225×g in a shaking incubator. Then, 1ml of overnight culture was 
transferred into a 250ml flask containing100ml of SOB medium and incubated at 
37
o
C with shaking at 225×g in a shaking incubator until the OD550 reached 0.4. The 
culture solution was then split into 8 × 12ml aliquots and placed on ice for 10-15 
minutes to cool down. DH5α bacteria was isolated by centrifuging at 2500×g for 10 
minutes at 4
o
C. The bacterial cell pellets were re-suspended in 8.25ml of pre-cooled 
RF1 buffer and incubated on ice for 10-15 minutes. After a further centrifuging at 
2500×g for 10 minutes at 4
o
C, the cell pellet was re-suspended in 2ml of RF2 buffer. 
The DH5α bacteria solution was dispensed into 1ml aliquots in cryovials, flash-frozen 
in liquid nitrogen and transferred immediately to -80
o
C freezer for storage (107). 
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2.2 Miniprep extraction of plasmid DNA 
For double mutant FABP5 DNA, Miniprep QIAgen extraction kit was used to extract 
plasmid DNA of pQE-32 expression vector (107). Ten mls of overnight growing 
bacteria (DH5α E. coli) in LB medium containing ampicillin was harvested by 
centrifuging (6,500 × g, 1min). Discarded the supernatant. Cell pellet was re-
suspended in 250μl of cell suspension buffer P1 (50mM TrisHCl pH8.0, 10mM EDTA 
and 100μg/ml RNaseA) by swinging. Then 250μl of cell lysis buffer P2 (200mM 
NaOH and 1% w/v SDS) was added to the bacterial suspension. The reagents were 
slowly mixed up by inversion of the Eppendorf for six times. Then 350μl of 
neutralization buffer N3 (4.2M Gu-HCl, 0.9M potassium acetate pH4.8) was added 
and mixed up by gentle reversal in eppendorf for six times. The mixture was 
centrifuged at 15,000×g for 10 minutes and the supernatant was moved to a Miniprep 
spin column. The column was centrifuged at 17,000×g for 1minute and the 
supernatant was removed. The column was then washed by adding 750μl of wash 
buffer PE (10mM Tris-HCl pH7.5 and 80% ethanol) and centrifuged at 17,000×g for 
1 minute. Repeat the centrifugation for 1 minute after discarding the flow through. 
The column was placed in a clean 1.5ml eppendorf, 40μl of distilled water was added. 
After the incubation for 1 minute at room temperature, the plasmid DNA was eluted 
by centrifuging at 17,000×g for 1minute. The DNA concentration was evaluated with 
a NanoDrop spectrophotometer (Labtech International, Ringmer, UK). The plasmid 
DNA was stored in -20℃ freezer (155). 
  
 
- 61 - | P a g e  
 
2.3 Digestion of plasmid DNA using restriction enzymes 
Plasmid DNA of double-mutant FABP5 was digested with two different restriction 
enzymes (KpnI and PstI) from vector pQE-32 to confirm the presence of insert or to 
produce the DNA fragment for further application. Empty plasmid pQE-32, the 
cloning vector pBluescript II SK harboring wtrFABP5 DNA and the cloning vector 
pBluescript II SK harboring dmrFABP5 DNA was digested with the same two 
restriction enzymes, respectively. The restriction digestion mixtures were prepared as 
shown in the following table (107).  
Table 2.1: The restriction enzyme digestion mixture (total volume 25µl)  
Reagent pQE-32  
(Empty) 
pBluescript II SK 
(dmrFABP5) 
pBluescript II SK 
(wtrFABP5) 
Water 0.5μl 5.5μl 17.5μl 
PstI 1μl 1μl 1μl 
KpnI 1μl 1μl 1μl 
Buffer 1 2.5μl 2.5μl 2.5μl 
DNA 20μl (2μg) 15μl (1μg) 3μl (3μg) 
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The above restriction digestion mixtures were incubated at 37℃ for 1.5 hours to 
produce a complete cleavage of template DNA. The enzyme activity was then 
inactivated by heating to 65℃ for 10 minutes and the resulting DNA fragments were 
analyzed by electrophoresis in agarose gels to confirm the successful cleavages. 
2.4 Analysis of DNA fragments by electrophoresis in agarose gel 
Agarose gel electrophoresis was performed in 1×TBE buffer. The agarose 
concentration was 0.8% to 2.0% (w/v) in the gel, according to DNA size. The agarose 
was dissolved in 200ml 1×TBE buffer by boiling in microwave for 2 minutes and 
cooled down for 20 minutes (40-50℃). Five μl safe view blue dye was then added to 
the gel for visualization of the DNA bands. The gel mixture was placed to 4℃ for 
solidification. DNA samples were prepared by adding 6× DNA loading buffer and 
dH2O to 20μl. Samples were heated at 65℃ for 5minutes and then loaded into each 
well of the gel. The sample run for 50 minutes in the gel at 90V electricity to separate 
the DNA fragments. Different sized DNA fragments separated by electrophoresis in 
the agarose gel were visualized to distinguish the vector and insert fragments on an 
UV transilluminator (155). 
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2.5. Purification of DNA from gels  
DNA fragments were purified from agarose gel by using a Wizard® SV Gel and PCR 
Clean-Up kit (Promega, WI, USA). Target fragments were cut off from the gel using a 
sterile blade. Each cut gel slice was weighed, then three times (W/V) buffer QG was 
added. The mixture was dissolved by heating at 50-60℃ in a water bath for 10 
minutes with occasional vortex. The melted agarose and DNA solution were applied 
to a QIA quick spin column (Qiagen, UK) and centrifuged for 1 minute at 16,000×g. 
The column was then washed by 750μl of PE buffer and centrifuged for another 1 
minute. The DNA fragments were collected by eluting from the column with 30μl of 
dH2O and the concentration of the DAN fragments was evaluated with Nano-Drop 
and DNA prepared from bacterial cells was kept at -20℃ (155). 
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2.6 DNA ligation 
The wild-type FABP5 cDNA fragment prepared in the way described in section 2.3. 
was inserted into the expression vector pQE-32 by T4 DNA ligase. The components 
of the ligation reaction mixtures were listed in the following table: 
Table 2.2: The ligation reaction mixture (155). 
Insert DNA (139ng/μl) 14μl 
Vector DNA pQE-32 (100ng/μl) 1.5μl 
Quick Ligation buffer 2μl 
T4 DNA Ligase 1μl 
Distilled water 1.5μl 
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2.7 Transformation of competent bacteria with vector DNA 
E. coli (DH5α) cells were taken out from -80℃ storage and unfrozen on ice. Ten μl 
ligation mixtures containing wtrFABP5- and dmrFABP5- expression constructs 
(contains about 50ng construct DNA) were added to 200ml LB broth with competent 
E. coli (DH5α) cells, respectively. The DNA constructs and E. coli cells were first 
mixed by gentle vortex, incubated on ice for half an hour, briefly heated at a 42℃ 
water bath for 1.5 minutes, and then immediately put on ice for 2 minutes. To each 
transformation vial, 800μl SOC reagent was added, and the mixture was then 
incubated at 37℃ in an orbit-shaking incubator for 1 hour at a shaking speed of 
150×g. Then, 200μl of transformed cells was removed and spread on the top of the 
ampicillin LB agar in a plate and incubated at 37℃ overnight (107). 
On the following day, several clones were picked up from each plate and   the plasmid 
DNA was selected from the culture of each colony. The restriction enzymes KpnI and 
PstI were used again to digest the expression construct and the digestion mixture was 
applied to electrophoresis in agarose gel. The resulting DNA fragments were 
visualized on an UV transilluminator. The success of cDNA insertion in the ligation 
reaction (the FABP5 cDNA was inserted into the pQE-32 vector) was confirmed by 
the appearance of a short FABP cDNA fragment. The method used for construction of 
expression vectors was the same as that described previously (107).  
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2.8 Expression and purification of wtrFABP5 and dmrFABP5 
The protocol of expression and purification of recombinant protein was carried out as 
explained in the QIAexpress Ni-NTA Fast Start Handbook. The protein blotting 
protocol was carried out as explained in the Bio-Rad Protein Blotting Guide. 
2.8.1 Growing E. coli cells and inducing protein expression 
Single colony harboring construct either pQE-32-wtrFABP5 or construct pQE-32-
dmrFABP5 was picked up from the selective antibiotic LB agar plate, and incubated 
in a 50ml flask containing 10ml LB medium with 100µg/ml ampicillin at 37℃ 
overnight. The overnight bacterial culture (10ml) was then transferred into a 1-litre 
flask containing 250ml of pre-warmed LB broth with 100µg/ml ampicillin and 
inoculated with shaking at 37°C until OD600 reached 0.6 (usually 60-90 minutes). 
Isopropylthiogalactoside (IPTG, Sigma, USA) was added to induce further protein 
expression at the concentration of 1mM for 4.5 hours. Cells were collected by 
centrifugation at 5000×g for 20 minutes and pellet was stored in -20℃.  
 
2.8.2 Protein purification 
The recombinant FABP5s produced in E. coli cells were purified with a Qiagen Ni-
NTA Fast Start Kit. Both wtrFABP5 and dmrFABP5 (fused with a 6×His-tag) were 
separated from bacterial proteins by affinity chromatography with a 6×His-tag 
antibody conjugated to Ni-NTA agarose in a column. Cell pellet was lysed by 10ml 
native lysis buffer for about 1 hour and the clean cell lysate supernatant was collected 
after centrifugation at 14,000 ×g for 30 minutes at 4℃. Five μl of supernatant was 
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taken for SDS-PAGE analysis to confirm the presence of relevant His-tag (conjugated 
with recombinant FABP5) bands. Then the supernatant was applied to a Ni-NTA 
column and 5μl flow-through fraction was collected for further SDS-PAGE analysis. 
The column was then washed for 3 times by 4ml native wash buffer. For each fraction, 
5μl  was collected for SDS-PAGE analysis. The FABP5 proteins (either wtr- or dmr- 
FABP5) conjugated to 6×His-tagged antibody in the column was eluted by 1ml native 
elution buffer twice. The recombinant protein (wtrFABP5 or dmrFABP5) was 
confirmed finally by the presence of the band detected with antiFABP5 antibody on 
the blot (155).   
2.8.3 Cleaning the recombinant protein by dialysis 
The D-Tube dialyzer (Novagen) was used to remove the buffer from purified 
recombinant protein. The D-Tube was treated with deionized water for 5minutes. The 
water was then removed and protein in the elusion buffer was added to the tube. Tube 
was placed into PBS in a beaker on a floating rack. The dialysis was conducted with 
gentle stirring in 4℃ for 3 hours and the protein was then stored in -80℃ after flash 
freezing in liquid nitrogen (155). 
 
2.8.4 Bradford assay 
Bradford assay was used to measure the concentrations of proteins. A standard curve 
was established by a serial concentrations of BSA (from 50-500μg/μl) in 50μl PBS. 
Five micro liter of protein samples were diluted with 50μl PBS. Controls and samples 
were incubated with 1ml of diluted (1/5) dye reagent (Bio-Rad GmbH, Munchen, 
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Germany), for 15 minutes before measuring the absorbance at 595nm using the 
MultiSkan plate reader (BioTek Instruments, USA). Standard curve (Figure 2.1) was 
used to calculate the concentration of proteins (156).  Since the linear ranges of target 
proteins detected in Western blotting  could not be tested in this assay, the quantitative 
analysis was not absolutely accurate. But the results of western blot showed the trend 
of changes of proteins under different treatments. 
 
Figure 2.1. Standard curve of Bradford assay. The standard curve showed the 
variation in the response of proteins in the Bradford assay. The R
2
=0.9991 which 
indicated the curve is linearized. The data allow comparisons to be made 
between estimates of protein content obtained with these protein standards (156).   
 
2.8.5 Sodium dodecyl sulphate-polyacrylamide protein gel electrophoresis 
(SDS-PAGE) 
y = 1.5203x - 0.0077 






























Standard curve (linear fit) 
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Sodium dodecyl sulphate-polyacrylamide protein gel electrophoresis is a very 
common method for separating proteins according to their molecular weight. This 
technique is based on the differential rates of migration of protein through a gel under 
the effect of an applied electrical field. A polyacrylamide gel is applied as a medium 
and sodium dodecyl sulfate (SDS) to denature the proteins. A plate sandwich of ready 
gel from Bio-Rad was performed and protein samples were added to 2×SDS-PAGE 
sample loading buffer, boiled at 95°C for 10 minutes and treated on ice for 2 minutes, 
then the samples were loaded. The gel with samples was run for 40-60 minutes at 
150V (155). 
2.8.6 Transfer of proteins from SDS gel to nitrocellulose membrane 
Proteins were Separated based on different molecular weight after SDS-PAGE. The 
proteins were transferred from SDS gel to a nitrocellulose membrane using the Bio-
Rad mini trans-blot system. Two sheets of Bio-Rad thick filter papers and the 
nitrocellulose membrane were treated in cold in1× transfer buffer for 5 minutes. The 
cassette, with black side down, was placed on a dish with transfer buffer and the 
cassette was assembled in following order (from black side on the bottom): a pre-wet 
fiber pad, 1 sheet of thick filter paper, equilibrated SDS gel, nitrocellulose membrane, 
1 sheet of thick filter paper and another pre-wet fiber pad. Air bubbles must be 
removed. The transfer was performed at 100V, 4℃ for 1 hour in cold in 1x transfer 
buffer (155). 
2.8.7 Immunoblotting for target protein detection 
The nitrocellulose membrane with transferred proteins was soaked in 20ml of 5% 
blocking solution (5g skimmed-milk in 100ml TBST) for an hour at room temperature 
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with gentle shaking. The membrane was then incubated with antibody in milk-TBS-T 
mixture in an appropriate concentration (Table 2.1) with gentle shaking at 4℃ 
overnight, respectively. Washing the membrane with 1× T-TBS for 10 minutes and 
repeated for 3 times to remove unbound primary antibody. The washed membrane 
was incubated with a secondary antibody in an appropriate concentration (Table 2.1) 
for an hour at room temperature, respectively. Washing the membrane again by using 
1× T-TBS 10 minutes and repeated for 3 times. The bound antibodies on the 
membrane were visualized with an ECL reagents kit (mixed with 1ml of Reagent A 
and of 1ml solution B) for 5 minutes at room temperature. The intensities of 
visualized protein bands were measured with an imaging analysis machine 
(ChemiDoc MP Imaging System, Bio-Rad, UK) (155). 
 
2.8.8 Correction of possible loading discrepancies 
An anti-β-actin antibody was used to hybridize each blot to normalize the possible 
loading variations: After the intensities of bands on the blot were measured by 
imaging analysis, the membrane was washed in 1× T-TBS with gentle shaking 
overnight. Then the membrane was incubated in 20ml of 5% blocking solution for 30 
minutes. Incubated membrane with anti-β-actin antibody at a 1:20,000 dilution for 30 
minutes at room temperature. Washing membrane with 1× T-TBS for 5 minutes for 3 
times. Secondary antibody was added after washing. The secondary antibody in 
1:20,000 dilution was added and incubated with the membrane for 30 minutes with 
gentle shaking at room temperature. Blots were washed respectively for three times 
with 1×T-TBS for 5 minutes again and bound β-actin bands were visualized with the 
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ECL detection and imaging analysis system. The process of recombinant protein 
production and purification is shown in the following figure: 




                        A 
 
                        B 
 
     
Figure 2.2. Recombinant protein production and purification. A) Western blot 
confirmation of the optimal experimental time points at which the maximum amount 
of recombinant protein was synthesized in bacterial cells. After the wild-type and the 
double-mutated FABP5 cDNAs were cloned into pQE32 expression vectors, 2 
recombinant FABP5s were produced in the BL21 strain of E. coli cells. Bacterial 
samples were removed once per hour from culture, totally for 5 hours after IPTG was 
added. Before loading, the total proteins from each lysed bacterial sample was 
quantified using a Bradford Assay kit (Bio-Rad, Hertfordshire, UK). DH2O was added 
to samples to ensure equal amount of protein were loaded. 6×His-tag bound protein 
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bands were tested by the Penta-His antibody. The wtrFABP5 protein synthesized in 
bacterial cells at different time points is shown in 7 separate lanes. B) Western blot 
analysis of different recombinant FABP5s purified by affinity chromatography on a 
Ni-NTA column. FABP5 protein was tested by monoclonal anti-human FABP5 
antibody (HycultR Biotech, UK ). At the final stage of the purification, 2 eluates were 
collected, Elution 1 and Elution 2 are the first and the second eluates, respectively. 
Immunodetection of the first and second elution of the purified recombinant FABP5s 
showed that the majority of protein is in Elution1. 
 
Table 2.3. Antibodies used in Western blot analysis. 
Target Protein Primary Antibody Secondary Antibody 
FABP5 Monoclonal Rabbit Anti-
human 
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2.9 Cell culture 
 
2.9.1 Routine cell culture 
Cell lines were cultured in flasks and incubated at 37℃ in a humidified incubator with 
5% (v/v) CO2. Three cell lines PNT2, 22Rv1 and PC3 were cultured in RPMI-1640 
medium supplemented with 10% (v/v) foetal calf serum (FCS), 2mM L-glutamine, 
100IU penicillin- 50μg/ml streptomycin (PEN-STREP). All routine culture media 
were replaced every other day. Authenticity of each cell line was confirmed by DNA 
fingerprinting or STR analysis (shown in Appendix) and cell culture was routinely 
examined for mycoplasma contamination every 3 weeks. The cell authenticity was 
performed by the department STR Test Centre and the certificates for each cell line 
was included I the appendix. The mycoplasma contamination test was conducted by a 
designated  department technician (155).  
 
2.9.2 Cells thawing 
Vials of cells were taken out from a liquid nitrogen storage tank and defrosted in a 37℃ 
water bath. Cells were moved to a universal tube containing 10ml complete medium 
and separated by centrifugation at 800 g for 3 minutes. The supernatant was discarded 
and the cell pellet was re-suspended in complete medium. Cells were placed in cell 
culture flask and incubated in an incubator at 37℃ with 5% (v/v) CO2 (155). 
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2.9.3 Cells sub-culture 
When cells grew to approximately 60-80% confluence, sub-culture was performed to 
split the culture into more flasks so that the cells can continue to grow. To start the 
sub-culture of the cells, the old medium was aspirated from the flask and flask was 
rinsed by PBS for 2 times. Adequate amount of 2.5% (v/v) trypsin/versene mixed 
solution was added into flask and incubated in an incubator for 3-5 minutes. Complete 
medium containing double amount of FSC was added to inactivate the effect of 
trypsin/versene mixture. Centrifugation at 800 g was applied for 3 minutes, re-
suspended cell pellet in complete medium in a new flask and incubated in an 
incubator at 37℃ with 5% (v/v) CO2 (155). 
 
2.9.4 Cell counting 
The number of cells was counted with an improved Neuberger double counting 
chamber haemocytometer. Cells were detached from the culture flask with the method 
as previously described. After thoroughly mixed, 10µl of cell suspension was loaded 
to a counting chamber of haemocytometer with 9 (3×3) squares. Then, cells were 
counted in four corner squares under the microscope. The total number of cells is 
calculated using the following equation:  
Total number of cells = Average cell count per square × Dilution × 10
4
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2.9.5 Freezing cells 
Cells were frozen down when they reached approximately 65-85% confluence. Cells 
were detached and washed as described in section 2.9.3. Cell pellets were re-
suspended with freezing medium (complete medium with 0.75% (v/v) DMSO). For 
each cryogenic vial, 1ml cell suspension was added and placed into a Nalgene cryo-
preserver box containing 250ml isopropyl alcohol. The box was then stored in a -80℃ 
freezer overnight before moving to a liquid nitrogen tank for long-term storage (155). 
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2.10. Detection of cellular apoptosis by Annexin V-FITC staining  
This staining was with Annexin V-FITC apoptosis detection kit following the protocol 
(Abcam, UK). Cell apoptosis was induced with 5 μM camptothecin. The cells were 
first treated by either wtrFABP5, dmrFABP5, SB-FI-26 or PBS for 48 hours, 
respectively. A number of 3×10
5
 cells were collected from each group and re-
suspended in 500 μl binding buffer. Five μl of Annexin V-FITC and 5μl of propidium 
iodide (PI) were added into the buffer and incubated in dark place at room 
temperature for 5 minutes. 
Samples were analyzed by flow cytometry with FACSCanto II Flow Cytometer (BD) 
using FITC signal detector (FL1) and phycoerythrin emission signal detector (FL2).  
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2.11. The assay of NFκB transcription factor activity test 
The DNA binding activity of NFκB in cell nucleus was detected with an NFκB 
transcription factor (p65) assay kit following the protocol of the manufacturer (Abcam, 
UK). Nuclear extracts of control cells (treated with PBS) and cells treated with 
wtrFABP5 or dmrFABP5 were collected with a nuclear extraction kit (Abcam, UK). 
 
2.11.1 Nuclear extraction 
Control cells (treated with PBS) and cells treated with wtrFABP5 or dmrFABP5 were 
grown to 70-80% confluence in flasks and 5×10
6
 cells were sub-cultured by 
trypsin/versene solution and collected from each group. Cell pellet was collected  and 
re-suspended in 500μl 1×Pre-extraction buffer, then flat on ice for 10 minutes. 
Samples were mixed and centrifuged at 10,000 g for 1 minute, then carefully removed 
the cytoplasmic extract from the nuclear pellet.  
A volume of 50μl of Extraction buffer with DTT and PIC mixture (1000:1) was added 
to each nuclear pellet. The extracts were flat on ice for 15 minutes with 5-10 seconds 
vortex every 3 minutes.  
Each suspension was centrifuged for 10 minutes at 12,000 g at 4℃ and supernatant 
was collected and transferred to another microcentrifuge tube. 
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2.11.2 NFκB transcription factor assay with ELISA method 
The transcription factor antibody binding buffer (10×) was diluted 1:10 by adding 
UltraPure water. The wash buffer (400×) was diluted 1:400, 5 ml of 400×wash buffer 
was diluted by adding 2 L UltraPure water and 1 ml of Polysorbate 20. Complete 
transcription factor binding assay buffer (CTFB) was prepared prior to use in 1.5 ml 
centrifuge tubes as shown in following table. 
 
Table 2.4. Preparation of Complete Transcription Factor Binding Assay Buffer. 
Reagents Volume/ 
well 
UltraPure water 73 μl 
Transcription factor 
binding assay buffer (4×) 
25 μl 
Reagent A 1 μl 
300mM DTT 1μl 
Total volume 100μl 
 
Move the 96-well plate and buffers to room temperature for warming. Unseal the 
plate and chose number of wells needed.  
Non-specific binding wells, positive control wells, specific competitor double-
stranded DNA (dsDNA) wells and test wells were set up in duplicates in different 
wells of a transcription factor NFκB 96-well strip plate as shown in figure 2.2. The 
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appropriate amout of reagents liste below to the designated wells as follows: 
Non-specific binding wells: 100μl CTFB 
Specific competitor dsDNA wells: 80μl of CTFB on the bottom and 10μl of 
Transcription Factor NFκB competitor dsDNA to designated wells. Then add 10μl of 
control cell lysate. 
Sample wells: add 90 μl of CTFB and then add 10 μl (5μg) of sample Nuclear Extract 
Positive control wells: add 90 μl of CTFB and then add 10 μl of positive control 
The plate was then sealed with cover and incubated at room temperature for 1 hour 
without agitation. The reagents in the wells were then removed and washed 5 times 
with 200 μl of 1× wash buffer. Remove any residual wash buffer after 5 times washing. 
The plate was incubated with NFκB primary antibody (1: 100) for 1 hour and washed 
5 times with 200μl of 1× wash buffer. Remove any residual wash buffer after 5 times 
washing. 
Then conjugated to goat anti-rabbit HRP antibody (1:100) was applied to each well  
for 1 hour and washed 5 times with 200μl of 1× wash buffer. Remove any residual 
wash buffer after 5 times washing. 
A volume of 100μl transcription factor-developing solution was added to each well 
for 30 min in the dark at room temperature. Before adding Transcription Factor Stop 
Solution, monitor the wells to turn medium to dark blue.  The stop solution was added 
and absorbance at 450nm was measured within five minutes. 
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Figure 2.2. 96-well strip plate format 
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2.12. Western blot analysis for apoptosis-related factors. 
Expression of proteins in control cells and cells treated with wtrFABP5 or dmrFABP5 
were detected by Western blot technique and  ECL detection system (Millipore, UK). 
Proteins were loaded and run with SDS-PAGE in a 12.5% (w/v) acrylamide gel, and 
transferred onto a nitrocellulose membrane (Hybond ECL, Amersham Pharmacia, 
Amersham, UK). Primary antibody against p-PPARγ (Ser 112) (Thermo Fisher, UK) 
was diluted at 1:200 and incubated with the blot overnight. After incubating with  
horseradish peroxidase-conjugated anti-rabbit IgG (Santa-cruz, USA) diluted at 1: 
10,000 protein bands were detected and measured by exposing the membrane in a 
imaging analysis machine (ChemiDoc MP Imaging System, Bio-Rad, UK). The 
primary antibodies against PPARγ, AKT, p-AKT (Ser 473), BAX, BCL-2, the 
cleaved-Capase-9 (Santa-Cruz, USA) and the cleaved-Caspase-3 (Cell Signaling, UK) 
were diluted at 1:200-500 and incubated with the blots for 1 hour. After incubating 
with horseradish peroxidase-conjugated anti-rabbit (AKT, p-AKT and cleaved-
Caspase-3) - or anti-mouse (PPARγ, BAX, BCL-2, cleaved-Caspase-9) - IgG (Santa-
Cruz, USA) diluted at 1:10,000, respectively, protein bands were detected and 
measured in the same way as p-PPARγ. The antibody against β-actin was used to 
quantify the actin bands on each blot to correct for possible loading discrepancies. 
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Table 2.5. Antibodies used in Western blot analysis. 
Target Protein Primary Antibody Secondary Antibody 
PPARγ Monoclonal Mouse anti-
















AKT Monoclonal Mouse anti-






p-AKT Monoclonal Mouse anti-
p-AKT (Ser 473) 






BAX Monoclonal Mouse anti-






BCL-2 Monoclonal Mouse anti-






Cleaved Caspase-9 Monoclonal Mouse anti-
Caspase-9  Antibody 





Cleaved Caspase-3 Monoclonal Rabbit anti-
Cleaved Caspase-3  
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2.13. Statistical analysis  
Student’s t-test was carried out using GraphPad Prism software to compare the 
differences of the means between control and experimental groups and the data is 
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3. Result 1: The effect of FABP5 inhibitors on prostate cancer cell 
apoptosis 
3.1 Introduction 
Previous work in our research group confirmed that FABP5 had a tumour-promoting 
effect on prostate cancer cells and this effect depended on its ability to bind to and to 
transport fatty acids from intracellular and extracellular sources into cells to activate 
their nuclear receptor PPARγ (107, 129). FABP5 binds to medium- and long- chain 







) (107, 149). In previous studies, we altered 2 








) and produced the 
mutant dmrFABP5 (107), which is almost incapable of binding to fatty acids, and 
which can suppress the biological activity of wtrFABP5 (150). 
Although both FABP5 inhibitors SB-FI-26 and dmrFABP5 can suppress the 
tumourigenicity of prostate cancer cells (147), the molecular mechanisms involved in 
their tumour-suppressing activities are not known and whether these inhibitors can 
affect the apoptosis of the prostate cancer cells is not fully investigated.  
The target of this chapter is to detect the effect of FABP5 and FABP5 inhibitors on 
apoptosis in prostate cancer cells. To investigate the possible relationship between 
FABP5 inhibitors and apoptosis in prostate cancer cells, sufficient quantities of 
wtrFABP5 and dmrFABP5 had been produced and purified using the experimental 
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procedures described in chapter 2. The chemically synthesized FABP5 inhibitor SB-
FI-26 was purchased from commercial source (Cayman Chemical Company, USA). 
Using these experimental materials, we first investigated whether FABP5 inhibitors 
were involved in promoting apoptosis in both the androgen-responsive 22Rv1 cells 
and the AR-negative PC3 cells; then assessed whether FABP5 inhibitors suppressed 
tumourigenicity of the cancer cells by promoting apoptosis.   
 
3.2 WtrFABP5 suppressed apoptosis of the prostate cancer cells 
WtrFABP5 was used to treat 22Rv1 and PC3 cells to test the change on apoptosis. 
The androgen-responsive prostate cancer cell line 22RV1 and the androgen-
independent cell line PC3 were cultured to 90% confluence and harvested; equal 
number (1×10
5
) of cells were then sub-cultured in triplicates. Each different dose 
(From 0.1µM to 1µM) of wtrFABP5 was added to each of the triplicate cultures and 
the cells were allowed to grow for a further 48h. Cells were harvested by centrifuge 
and Annexin V-FITC staining and flow cytometry were then performed to each group. 
The dot graph and histogram graph records were collected from flow cytometry and 
the records of control groups and optimal dose of wtrFABP5 (0.5µM) groups were 
shown in Figure 3.1.  
For each dot graph, dots in the first quadrant (up right) represent the late stage 
apoptotic cells. Dots in the second quadrant (up-left) represent dead cells and cell 
debris. Dots in the third quadrant (low-left) represent normal living cells, which do 
not undergo apoptosis. Dots in the fourth quadrant (low right) represent cells 
undergoing apoptosis. For the histograms, the peak on the left represents living cells 
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without undergoing apoptosis, the right peak represents apoptotic cells.  
The results of flow cytometry quantitative analysis shown in Figure 3.1 and Figure 
3.2 revealed that the apoptosis rate of 22Rv1 cells was significantly higher than that 
of PC3 cells by 6.48% (p<0.01, Student’s t-test) with the treatment of PBS (Figure 
3.2). For the groups treated with wtrFABP5, all doses used produced reductions in 
apoptosis and the highest reduction was achieved in both cell lines with 0.5 µM 
wtrFABP5. Higher doses produced no more reductions in apoptosis. In 22Rv1 cells, 
when treated with this optimal dosage of wrtFABP5, 10.30% of cells underwent 
apoptosis. It is a significant reduction (17.18%) compared with that of control group 
(p<0.05, Student’s t-test). Thus, wtrFABP5 treatment reduced apoptotic fraction of the 
cells by 40.08% in 22Rv1 culture. In PC3 cells, the optimal dose of wtrFABP5 
reduced the fraction of cells undergoing apoptosis by 3.03% (p<0.05, Student’s t-test) 
when compared with that of control (10.70%). Therefore, in wtrFABP5-treated PC3, 
the apoptotic cells were reduced by 28.3%, compared to that in the control PC3 cells. 
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Figure 3.1. Records of dot graph and histogram graph of wtrFABP5 treated 22Rv1 
and PC3 cells. 1, dot graph record of control 22RV1 cells (treated with PBS). 2, 
histogram record of control 22RV1 cells. 3, dot graph record of control PC3 cells 
(treated with PBS). 4, histogram record of control PC3 cells. 5, dot graph record of 
22RV1 cells treated with 0.5µM wtrFABP5. 6, histogram record of 22RV1 cells 
treated with 0.5µM wtrFABP5. 7, dot graph record of control PC3 cells treated with 
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Figure 3.2. Line chart of percentages of the apoptotic cells in 22RV1 and PC3 cell 
lines treated with 4 different doses of wtrFABP5, respectively. Results were obtained 
from three separate measurements (mean ± SE) and the differences between the 
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3.3 Chemical inhibitor SB-FI-26 promote apoptosis of the prostate cancer cells 
Chemical inhibitor of FABP5, SB-FI-26, was used to treat 22Rv1 and PC3 cell lines 
and the effect on apoptosis was tested. 22RV1 and PC3 cell lines were cultured to 90% 
confluent and harvested; equal number (1×10
5
) of cells were then sub-cultured in 
triplicates. Each different dose (From 50µM to 150µM) of SB-FI-26 was added to 
each triplicate culture and the cells were continued to grow for 48h. Cells were 
harvested by centrifuge and Annexin V-FITC staining and flow cytometry were then 
performed to each group. The dot graph and histogram graph records were collected 
from flow cytometry and the records of control groups and highest dose of SB-FI-26 
(150µM) groups were shown in Figure 3.3.  
Quantitative analysis of flow cytometry showed that all used doses of SB-FI-26 
promoted apoptosis and the increase was positively correlated to the increase in dose. 
With the treatment of 150μM of SB-FI-26, 46.6% of 22Rv1 cells underwent apoptosis, 
a significant increase of 29.40% over that (17.2%) in the control (p<0.001, Student’s 
t-test). Thus, SB-FI-26 produced 1.71 fold more apoptotic cells in 22Rv1 cultures 
(Figure 3.4). In PC3 cells, 150μM of SB-FI-26 significantly increased by 7.78% of 
the proportion of cells undergoing apoptosis (p<0.05, Student’s t-test) when compared 
with that of the control (10.70%). Thus, there was 0.72 fold more cells undergoing 
apoptosis in SB-FI-26-treated PC3 cells in comparison with the control (Figure 3.4). 
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Figure 3.3. Records of dot graph and histogram graph of SB-FI-26 treated 22Rv1 and 
PC3 cells. 1, dot graph record of control 22RV1 cells (treated with PBS). 2, histogram 
record of control 22RV1 cells. 3, dot graph record of control PC3 cells (treated with 
PBS). 4, histogram record of control PC3 cells. 5, dot graph record of 22RV1 cells 
treated with 150µM SB-FI-26. 6, histogram record of 22RV1 cells treated with 
150µM SB-FI-26.  7, dot graph record of control PC3 cells treated with 150µM SB-
































- 92 - | P a g e  
 
 
Figure 3.4. Line chart of percentages of the apoptotic cells in 22RV1 and PC3 cell 
lines treated with 4 different doses of SB-FI-26, respectively. Results were obtained 
from three separate measurements (mean ± SE) and the differences between the 
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3.4 DmrFABP5 promote apoptosis of the prostate cancer cells 
The effect of the dmrFABP5 on apoptosis of 22Rv1 and PC3 cells was studied and the 
results were shown below. 22RV1 and PC3 cell lines were cultured to 90% confluent 
and harvested; equal number (1×10
5
) of cells were then sub-cultured in triplicates. 
Each different dose (From 0.1µM to 1µM) of dmrFABP5 was added to each triplicate 
culture and the cells were continued to grow for 48h. Cells were harvested, Annexin 
V-FITC staining and flow cytometry were then performed to each group. As shown by 
Figure 3.5 and Figure 3.6, dmrFABP5 promoted apoptosis in both cell lines. The dot 
graph and histogram graph records were collected from flow cytometry and the 
records of control groups and optimal dose of dmrFABP5 (0.5µM) groups were 
shown in Figure 3.5. 
With the treatment of dmrFABP5, quantitative analysis of flow cytometry showed that 
all groups had increased apoptosis rates and the highest increase was achieved in both 
cell lines when 0.5 µM dmrFABP5 was used (Figure 3.6). Higher dose in dmrFABP5 
did not produced more significant increases in apoptosis. In 22Rv1 cells, with the 
treatment of optimal dosage of dmrFABP5, 40.31% of cells underwent apoptosis, a 
significant increase by 23.12% from that (17.18%) in the control (p<0.001, Student’s 
t-test). Thus, dmrFABP5 treatment produced 134.60% more apoptotic cells in 22Rv1 
cells. In PC3 cells, the optimal dose of dmrFABP5 produced 26.46% of cells 
undergoing apoptosis; or an increase in the proportion of cells undergoing apoptosis 
by 15.76% (p<0.001, Student’s t-test) when compared with that of the control 
(10.70%) (Figure 3.6). Therefore, dmrFABP5 produced 1.47 fold more cells 
undergoing apoptosis in PC3 cells. 
 





Figure 3.5. Records of dot graph and histogram graph of dmrFABP5 treated 22Rv1 
and PC3 cells. 1, dot graph record of control 22RV1 cells (treated with PBS). 2, 
histogram record of control 22RV1 cells. 3, dot graph record of control PC3 cells 
(treated with PBS). 4, histogram record of control PC3 cells. 5, dot graph record of 
22RV1 cells treated with 0.5µM dmrFABP5. 6, histogram record of 22RV1 cells 
treated with 0.5µM dmrFABP5.  7, dot graph record of control PC3 cells treated with 
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Figure 3.6. Line chart of percentages of the apoptotic cells in 22RV1 and PC3 cell 
lines treated with 4 different doses of SB-FI-26, respectively. Results were obtained 
from three separate measurements (mean ± SE) and the differences between the 
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3.5 Discussion 
FABP5-related signal transduction pathway plays an important role in promoting 
malignant progression of CRPC cells and suppression of FABP5 to inhibit the 
tumorigenicity and metastasis of the prostate cancer cells (107, 123, 135, 147). 
Previously, studies of FABP5 were mainly focused on its tumorigenicity and 
metastasis promoting effect (107, 129, 132). It is also suggested that fatty acids 
carried by FABP5 can activate PPARγ to trigger FABP5-PPARγ-VEGF signaling 
pathway, which is novel target for therapeutic intervention or angiogenesis inhibition 
(135). Furthermore, one of the molecular mechanisms for the FABP5 inhibitors could 
be related to cellular apoptosis (107). Here in order to study the possible relationship 
between the suppressive effect of FABP5 inhibitors on cell apoptosis, the moderately 
malignant androgen sensitive 22Rv1 cells and the highly malignant androgen 
independent PC3 cells were treated with wtrFABP5 first and then treated with two 
FABP5 inhibitors: the chemical inhibitor SB-FI-26 and the bio-inhibitor dmrFABP5. 
SB-FI-26, a chemically synthesized inhibitor of FABP5, exhibited an ability to 
suppress both tumorigenicity and metastasis of prostate cancer (147). It can 
competitively bind to FABP5 to prevent intracellular and extracellular fatty acids 
from being transported into the cytoplasm and hence to reduce the cellular fatty acid 
uptake (147). The reduced fatty acid uptake can lead to a reduction or cessation of the 
fatty acid activation to their nuclear receptor PPARγ, and thus inhibited the biological 
activity of PPARγ.  DmrFABP5 has a very similar structure to that of wtrFABP5, but 
is almost unable to bind to fatty acids (107), and does not affect the cellular fatty acid-
uptake. Although the mechanism involved is not clear currently, dmrFABP5 can also 
reduce the biological activity of PPARγ, as that caused by SB-FI-26. Thus it was 
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suggested that both SB-FI-26 and dmrFABP5 significantly suppressed the 
tumorigenicity and metastasis of prostate cancer (147, 150) via suppressing the 
biological activation of the nuclear fatty acid-receptor PPARγ.  
In this chapter, treatment with wtrFABP5 significantly suppressed apoptosis in both 
22Rv1 (40%) and PC3 (28.3%) cells (Fig 3.2), indicating that FABP5 possibly 
promote the malignant progression of the CRPC cells by suppressing apoptosis, or at 
least, suppressing apoptosis is a part of the mechanisms involved in the cancer-
promoting effect of FABP5. As shown in figure 3.4, treatment with 150μM SB-FI-26 
caused 1.71 and 0.72 fold more cells to undergo apoptosis in 22Rv1 and PC3, 
respectively. Treatments with 0.5µM dmrFABP5 triggered 1.34 fold and 1.47 fold 
more cells to undergo apoptosis in 22Rv1 and PC3 cells, respectively (Fig 3.6). These 
results suggested that, while the increased level of FABP5 may significantly suppress 
apoptosis in prostate cancer cells,  the opposite effect was achieved when cells were 
treated with inhibitors SB-FI-26 or dmrFABP5, which demonstrated that both FABP5 
inhibitors suppressed prostate cancer by promoting the cancer cells to undergo 
apoptosis. These results provided a theoretical basis for possible therapeutic strategies 
for CRPC by inducing apoptosis obtained by FABP5 inhibitors. Although these results 
are very encouraging, further investigations are needed on the molecular mechanisms 
of how FABP5 affects cellular apoptosis and how the highly suppressed apoptosis by 
FABP5 can be increased by the FABP5 inhibitors.  
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Previously, it was found that  FABP5 expression was highly increased in prostate 
cancer cells and the increased FABP5 level is significantly correlated with the 
increasing malignancy of the cancer cells (107, 129). Since in the physiological state, 
the biological function of FABP5 is to transporting fatty acids into cells, the increased 
FABP5 in prostate cancer cells can transport a large amount of fatty acids into the 
cancer cells (107). While most of these fatty acids are used as alternative energy 
sources, the excessive amount of fatty acids were transported into nucleus (157). 
FABP5 performed as signaling molecules to activate its nuclear receptor PPARγ (135). 
When PPARγ is activated by fatty acids and is phosphorylated, it can suppress the 
nuclear membrane and promoted the downstream cancer-related genes  through DNA 
response element (PPRE) which may lead to enhanced tumourigenicity and metastasis 
with promoting angiogenesis and suppressing apoptosis (107, 158). 
Further studies revealed that FABP5- PPARγ- VEGF may gradually replace the AR-
related signal pathway in the CRPC cells to play a predominant role in promoting 
malignant progression in CRPC cells (123, 135, 137). While wtrFABP5 promoted 
malignant progression through affect PPARγ, the inhibitors of FABP5 (SB-FI-26 and 
dmrFABP5) have an exactly the opposite effect on PPARγ, and they inhibited the 
malignant progression of the cancer cells through reversing the biological function of 
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the wtrFABP5 (147, 150). Although both wtrFABP5 and its two inhibitors affect the 
malignant progression of the prostate cancer cells through interfering the biological 
activity of PPARγ, it is not clear whether their influence on apoptosis of the cancer 
cells is via PPARγ.   
The target of this chapter is to identify the effect of wtrFABP5 and dmrFABP5 on 
PPARγ activation during the process of influencing apoptosis in prostate cancer cells. 
In order to investigate the molecular mechanisms involved in how FABP5 and its two 
inhibitor exhibited any effect on the biological activity of PPARγ during the processes 
of influencing apoptosis, we first treated prostate cancer cells with wtrFABP5 to 
investigate whether the biological activity of PPARγ was increased. Then we treated 
the cancer cells with two FABP5 inhibitors to investigate whether the inhibitors can 
influence the biological activity of PPARγ. Since the effect of SB-FI-26 on PPARγ 
has already investigated in our previous work (147), the here we focused on the 
conformation of wtrFABP5 and dmrFABP5 . 
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4.2. Levels of FABP5, PPARγ and p-PPARγ in benign and malignant prostate 
epithelial cells 
Levels of of the FABP5 were detected by Western blot and the results were shown in 
Figure 4.1 (A, B). The benign PNT2 cells, the androgen-sensitive 22RV1 cells and the 
androgen-independent PC3 cells were cultured to 80% confluence, harvested and 
disrupted with a cell lyse buffer. Cell extracts were first subjected to SDS-PAGE and 
then Western blot analysis. An antibody against non-muscle β-actin was applied with 
each blot to correct possible loading discrepancies. Based on the bands in Figure 4.1A, 
level of FABP5 in the benign PNT2 cells were much lower than those in the medium 
malignant 22Rv1 and in the highly malignant PC3 cells. When the level of FABP5was 
set at 1 in PNT2 cells, its relative levels were greatly increased to 4.90±0.37 and 
42.47±1.53 in 22Rv1 and PC3 cells, respectively (Figure 4.1B). 
Level of of the PPARγ was measured by Western blot and the results were shown in 
Figure 4.2 (A, B). Based on the bands in Figure 4.2A, level of PPARγ in the benign 
PNT2 cells were much higher than those in the medium malignant 22Rv1 and in the 
highly malignant PC3 cells. Level of the phosphorylated form PPARγ (biologically 
activated form p-PPARγ) was measured by Western blot and the result was shown in 
Figure 4.2 (C, D). Based on the bands in Figure 4.2C, the expression of p-PPARγ was 
greatly increased in the malignant cells comparing with those in PNT2 cells. While 
the level of p-PPARγ was set at 1 in PNT2 cells, its relative levels were greatly 
increased to 18.74±2.46 and 16.47±1.45 in 22Rv1 and PC3 cells, respectively 
(p<0.01, Student t-test) (Figure 4.2D). 
 
 




       B 
 
Figure 4.1. Levels of FABP5 in benign and malignant prostate cells by Western blot. 
A) Western blot analyses of FABP5 expression in the benign PNT2 cells, moderately 
malignant 22RV1 and highly malignant PC3 cells. B) Quantitative assessment of the 
relative levels of FABP5 by densitometry scanning of the intensities of the bands on 
each blot. The level of FABP5 in the benign PNT2 cells was set at 1; the levels of 
other cell lines on the same blot were calculated by relating to that of PNT2. Results 
were obtained from three separate measurements (mean ± SE, n=3), the differences 
between the control PNT2 and 22Rv1, PC3 cells were assessed by 2-tailed unpaired 







































      
     
Figure 4.2. Levels of PPARγ and p-PPARγ in benign and malignant prostate cells. A) 
Western blot analyses of FABP5 expression in the benign PNT2 cells, moderately 
malignant 22RV1 and highly malignant PC3 cells. B) Quantitative assessment of the 
relative levels of FABP5 by densitometry scanning of the intensities of the bands on 
each blot. The level of PPARγ in the benign PNT2 cells was set at 1; the levels of 
other cell lines on the same blot were calculated by relating to that of PNT2. C) 
Western blot analyses of FABP5 expression in the benign PNT2 cells, moderately 
malignant 22RV1 and highly malignant PC3 cells. D) Quantitative assessment of the 
relative levels of FABP5 by densitometry scanning of the intensities of the bands on 
each blot. The level of p-PPARγ in the benign PNT2 cells was set at 1; the levels of 
other cell lines on the same blot were calculated by relating to that of PNT2. Results 
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between the control PNT2 and 22Rv1, PC3 cells were assessed by 2-tailed unpaired 
Student’s t test. 
 
4.3. The effect of wtrFABP5 and dmrFABP5 on levels of PPARγ and p-PPARγ 
expression in PC3 cells 
The effect of wtrFABP5 and dmrFABP5 on level of PPARγ expression in PC3 cells 
was measured by Western blot (Fig 4.3A,B). PC3 cells were cultured to 80% and 
counted, equal number (1×10
5
) of cells were then sub-cultured in triplicates: the 
control group was treated with PBS, the other 2 groups were treated with either 
0.5μM wtrFABP5 or 0.5μM dmrFABP5 for 48 hours, respectively. All the cells were 
harvested and disrupted with a cell lyse buffer. Cell extracts were first subjected to 
SDS-PAGE and then Western blot analysis. An antibody against non-muscle β-actin 
was incubated with each blot to correct possible loading discrepancies. As shown in 
Figure 4.3, wtrFABP5 and dmrFABP5 produced no obvious changes in the sizes of 
the bands (A) and the quantitative assessments showed that neither wtrFABP5 nor 
dmrFABP5 treatment produced significant changes to the levels of both PPARγ 
(p>0.05, Student T-test) (B).  
The effect of wtrFABP5 and dmrFABP5 on level of p-PPARγ expression and in PC3 
cells was measured by Western blot (Fig 4.3C,D). As shown in Figure 4.3, treatment 
with wtrFABP5 promoted the expression of p-PPARγ (C). Quantitative analysis 
showed that wtrFABP5 produced a significant increase (p<0.001, Student T-test) in p-
PPARγ level by about 39% (D). Treatment with dmrFABP5 suppressed the expression 
of p-PPARγ (C). Quantitative analysis showed that significant reduction (p<0.001, 
Student T-test) was produced in level of p-PPARγ by about 48% (D).  
 






Figure 4.3. The effect of wtrFABP5 and dmrFABP5 on levels of PPARγ and p-PPARγ 
in PC3 cells. A) Western blot analyze of the effects of the  treatments with PBS 
(Control), 0.5µM wtrFABP5 and 0.5µM dmrFABP5, respectively, on levels of PPARγ 
expression. B) Quantitative assessments by densitometry scanning of the intensities of 
the blot bands representing relative levels of PPARγ. The level of the control band 
(treated with PBS) in each panel was set at 1. The levels in cells treated with 0.5µM 
wtrFABP5 and dmrFABP5 were calculated, respectively, by relating to that in control. 
C) Western blot analyze of the effects of the treatments with PBS (Control), 0.5µM 
wtrFABP5 and 0.5µM dmrFABP5, respectively, on levels of p-PPARγ expression. D) 
Quantitative assessments by densitometry scanning of the intensities of the blot bands 
representing relative levels of p-PPARγ. The level of the control band (treated with 
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dmrFABP5 were calculated, respectively, by relating to that in control. Results were 
obtained from three separate measurements (mean ± SE, n=3), the differences 
between the control and treatments were assessed by 2-tailed unpaired Student’s t test. 
 
4.4. Discussion 
PPARγ is located on nuclear membrane,  it is highly expressed in adipose tissue and 
plays an important role to regulate adiposity and insulin sensitivity (159). Recent 
studies confirmed that PPARγ had key influence in promoting malignant progression 
of prostate cancer (160, 161). Our previous study suggested that the FABP5-PPARγ-
VEGF was a key signaling pathway in CRPC malignant signals transduction (135). 
While wtrFABP5 increased the level of p-PPARγ and dmrFABP5 has an opposite 
effect, the promoting effect of wtrFABP5 on p-PPARγ in prostate cancer cells could 
be completely reversed by dmrFABP5 when both were used together. Thus it was 
concluded that dmrFABP5 suppressed the tumorigenicity and metastasis by reversing 
the promoting effect of wtrFABP5 on p-PPARγ (150). Some studies also indicated 
that PPARγ could affect cell growth and apoptosis by targeting AKT pathway in 
human cells, and changes of expression levels of PPARγ were found when human 
cancer cells underwent apoptosis (165, 166). Recently, patients with CRPC are not 
curable and no effective therapy has been developed. Therefore, targeting CRPC is an 
imperative clinical requirement. In this work, we focused on PC3 cell line which was 
an androgen-independent CRPC cells.  
In this study, results showed that the total PPARγ levels in 22Rv1 and PC3 cells were 
much lower than that in the benign PNT2 cells, but the p-PPARγ levels in 22Rv1 and 
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PC3 cells were significantly higher (18.74± 2.46 fold and 16.47± 1.45 fold, 
respectively) than that in PNT2 (Fig 4.2). Results also showed that expressions of  
PPARγ were not significantly different in PC3 cells when treated with wtrFABP5 or 
dmrFABP5. However, the level of p-PPARγ was significantly increased in highly 
malignant PC3 cells by about 39% when treated with wtrFABP5(Fig 4.3A,B), 
whereas treatment with dmrFABP5 significantly reduced the level of p-PPARγ by 
about 48% in PC3 cells. This result suggested dmrFABP5 played a completely 
opposite role to wtrFABP5 and suppressed the activation of PPARγ (Fig 4.3C,D). 
Therefore, it is possible that the increased apoptosis shown in previous chapter is 
caused by the reduction of the p-PPARγ level.  
To further study how p-PPARγ could affect apoptosis, levels of some factors related to 
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5. Result 3: DmrFABP5 suppresses AKT and NFκB signaling 
pathway activities in prostate cancer cells 
5.1. Introduction 
Now that we have demonstrated that wtrFABP5, its inhibitors SB-FI-26 and 
dmrFABP5 can modulate PPARγ (162, 163). Therefore, it is very likely that the effect 
on apoptosis produced by these molecules are through PPARγ. However, whether and 
how PPARγ is exactly connected to apoptosis of the prostate cells is not known. Some 
recent studies reported that AKT had a key influence on regulating apoptosis in 
different types of cancers, including prostate cancer (164-166).  Previous 
investigations in other cell systems suggested that activated AKT pathway is often 
associated with the biologically active PPARγ (167-169). Despite of these previous 
observations in other cells systems, it is not clear whether PPARγ may regulate AKT 
pathway to influence apoptosis in prostate cancer cells.   
AKT pathway, also named as PI3K-AKT- signal pathway, was identified to be an 
important pathway, which controls cell survival and apoptosis. This pathway can be 
activated through the stimulation of PI3K (170-172), which promotes the 
phosphorylation of AKT at Thr-308 or Ser-473 (173). Biologically activated AKT (p-
AKT) can regulate individual members of the downstream BCL-2 family factors to 
disrupt their balance. This may lead to a reduced level of Caspase-9 and hence 
suppression of apoptosis (174-176).  
Nuclear factor (NF)- κB (NFκB) is a protein that controls DNA transcription, cytokine 
production, cell survival and apoptosis in human cells (177-179). Some kinases, 
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including AKT, can influence the upstream factors of the NFκB pathway. For example, 
phosphorylated AKT at Thr 308 or Ser 473 can up-regulate the p65 subunit of NFκB 
(180, 181). Some stimulations could cause the phosphorylation, ubiquitination and 
subsequent degradation of IκB proteins, thereby enabling translocation of NFκB into 
the nucleus (182). NFκB transcription factors bind to DNA sequences as dimers to 
regulate the downstream genes expression involved in cell growth and apoptosis (183-
185).  Although NFκB pathway plays an important role in malignant progression, it is 
not known whether it is related to PPARγ in prostate cancer cells.  
The target of this chapter is to access the possible effect of wtrFABP5 and dmrFABP5 
on survival pathways AKT and NFκB during the process of influencing apoptosis in 
prostate cancer cells. To investigate the possible relationship of PPARγ and AKT 
pathway or NFκB  pathway, we first tested levels of AKT and p-AKT expression in 
prostate cancer cells in this set of experimental work. Then we investigated the 
changes in levels of AKT, p-AKT after the treatment of either wtrFABP5 or 
dmrFABP5. We also investigated the  changes in the activity of NFκB factors 
produced by the treatment of either wtrFABP5 or dmrFABP5 in prostate cancer cells. 
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5.2. Levels of AKT and p-AKT in benign and malignant prostate epithelial cells 
Levels of of AKT were measured by Western blot and the results were shown in Figure 
5.1 (A, B). The benign PNT2 cells, the androgen-sensitive 22RV1 cells and the 
androgen-independent PC3 cells were cultured to 80% confluence, harvested and 
disrupted with a cell lyse buffer. The cell extracts were first subjected to SDS-PAGE 
and then Western blot analysis. An antibody against non-muscle β-actin was 
incubated with each blot to correct possible loading discrepancies. Based on the bands 
in Figure 5.1A, level of total AKT in the benign PNT2 cells were much higher than 
those in the medium malignant 22Rv1 and in the highly malignant PC3 cells.  
Levels of p-AKT were measured by Western blot and the results were shown in 
Figure 5.1 (C, D). Based on the bands in Figure 5.1C, the expression of p-AKT was 
greatly increased in the malignant cells comparing with those in PNT2 cells. When 
the level of p-AKT was set at 1 in PNT2 cells, its relative levels were greatly 
increased to 1.27±0.09 and 2.57±0.3 in 22Rv1 and PC3 cells, respectively (p<0.01, 
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A                                                                          C 
 
B                                                                           D 
       
Figure 5.1. Levels of AKT and p-AKT in benign and malignant prostate cells by 
Western blot. A) Western blot analyses of AKT expression in the benign PNT2 cells 
and in the malignant 22RV1 and PC3 cells. B) Quantitative assessment of the relative 
levels of AKT by densitometry scanning of the intensities of the bands on each blot. 
The level of each of AKT in the benign PNT2 cells was set at 1; levels of other cell 
lines on the same blot were calculated by relating to that of PNT2. C) Western blot 
analyses of p-AKT expression in the benign PNT2 cells and in the malignant 22RV1 
and PC3 cells. D) Quantitative assessment of the relative levels of p-AKT by 
densitometry scanning of the intensities of the bands on each blot. The level of each 
of p-AKT in the benign PNT2 cells was set at 1; the levels of other cell lines on the 
same blot were calculated by relating to that of PNT2. Results were obtained from 
three separate measurements (mean ± SE, n=3), the differences between the control 
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5.3. The effect of wtrFABP5 and dmrFABP5 on levels of AKT and p-AKT 
expression in PC3 cells 
The effect of wtrFABP5 and dmrFABP5 on levels of AKT expression and in PC3 cells 
were measured by Western blot (Fig 5.2). The androgen-independent cancer cell line 
PC3 were cultured to 80% and counted, equal number (1×10
5
) of cells were then sub-
cultured in triplicates: the control group was treated with PBS, the other 2 groups 
were treated with either 0.5μM wtrFABP5 or 0.5μM dmrFABP5 for 48 hours, 
respectively. All the cells were harvested and disrupted with a cell lyse buffer. The 
cell extracts were first subjected to SDS-PAGE and then Western blot analysis. An 
antibody against non-muscle β-actin was incubated with each blot to correct possible 
loading discrepancies. As shown in Figure 5.2, wtrFABP5 and dmrFABP5 produced 
no obvious changes in the sizes of the bands (A) and the quantitative assessments 
showed that neither wtrFABP5 nor dmrFABP5 treatment produced significant 
changes to the levels of both AKT (p>0.05, Student T-test) (B).  
The effect of wtrFABP5 and dmrFABP5 on levels of p-AKT expression and in PC3 
cells were measured by Western blot (Fig 5.2). The androgen-independent cancer cell 
line PC3 were cultured to 80% and counted, equal number (1×10
5
) of cells were then 
sub-cultured in triplicates: the control group was treated with PBS, the other 2 groups 
were treated with either 0.5μM wtrFABP5 or 0.5μM dmrFABP5 for 48 hours, 
respectively. All the cells were harvested and disrupted with a cell lyse buffer. The 
cell extracts were first subjected to SDS-PAGE and then Western blot analysis. An 
antibody against non-muscle β-actin was incubated with each blot to correct possible 
loading discrepancies. As shown in Figure 5.2, treatment with wtrFABP5 promoted 
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the expression of p-AKT (C). Quantitative analysis showed that wtrFABP5 produced 
a significant increase (p<0.001, Student T-test) in p-AKT level by about 69% (D). 
Treatment with dmrFABP5 suppressed the expression of p-AKT (C). Quantitative 
analysis showed that significant reduction (p<0.001, Student T-test) was produced in 
level of p-AKT by about 21% (D).  
 
 
A                                                                             C 
   
 
B                                                             D 
  
Figure 5.2. The effect of wtrFABP5 and dmrFABP5 on levels of AKT in PC3 cells. A) 
Western blot analyze of the effects of the  treatments with PBS (Control), 0.5µM 
wtrFABP5 and 0.5µM dmrFABP5, respectively, on levels of AKT expression. B) 
Quantitative assessments by densitometry scanning of the intensities of the blot bands 
representing relative levels of AKT. The level of the control band (treated with PBS) 
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dmrFABP5 were calculated, respectively, by relating to that in control. C) Western 
blot analyze of the effects of the  treatments with PBS (Control), 0.5µM wtrFABP5 
and 0.5µM dmrFABP5, respectively, on levels of p-AKT expression. D) Quantitative 
assessments by densitometry scanning of the intensities of the blot bands representing 
relative levels of p-AKT. The level of the control band (treated with PBS) in each 
panel was set at 1. The levels in cells treated with 0.5µM wtrFABP5 and dmrFABP5 
were calculated, respectively, by relating to that in control. Results were obtained 
from three separate measurements (mean ± SE, n=3), the differences between the 
control and treatments were assessed by 2-tailed unpaired Student’s t test. 
 
5.4. The effect of dmrFABP5 on NF-κB activity in PC3 cells 
The effect of wtrFABP5 and dmrFABP5 on NF-κB transcription factor activity in PC3 
cells was measured with a transcription factor-binding assay. As shown in Fig 5.3, 
when the level of NF-κB transcription factor activity in the benign PNT2 cells was set 
at 1; the level in the PC3 cells was significantly (p<0.05, Student’s t-test) increased to 
1.09 ± 0.02. The treatment of the PC3 cells with wtrFABP5 significantly (Student’s t-
test, p<0.0001) increased the NF-κB transcription factor activity by 24.77% to 1.36 ± 
0.01. The treatment with dmrFABP5 significantly (p<0.0005, Student’s t-test) reduced 
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Figure 5.3. The effect of dmrFABP5 on NF-κB activity in PC3 cells. Quantitative 
analysis of relative OD level of each group was made and the OD level of PNT2 
group was set at 1; the levels in wtrFABP5-treated and dmrFABP5-treated PC3 cells 
were calculated by relating to that in control PC3 cells. Results were obtained from 
three separate measurements (mean ± SE, n=3), the differences between the control 
and treatments were assessed by 2-tailed unpaired Student’s t test. 
 
5.5. Discussion 
Previous results demonstrated that FABP5 affected cell apoptosis by regulating the  
activation of PPARγ and the inhibitor of FABP5 played opposite roles to FABP5 to 
influencing the biological activity.  To study the molecular mechanism of how p-
PPARγ could affect apoptosis, we investigated its effect on the PI3K-AKT- signal 
pathway, which controls cell survival and apoptosis. Other studies demonstrated that 
the activation of AKT promotes cell survival and reduces apoptosis in different types 
of cancer cells including prostate cancer (164-166, 186-188). Some studies reported 
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lead to a reduction of the cleavage of Caspase-9 (174-176). AKT can also influence 
the upstream factor p65 subunit of the NFκB pathway (180, 181), which triggers the 
activation of NFκB and then regulate the expression of downstream genes involved in 
cell growth and apoptosis (183-185). 
In this work, when PC3 cells were treated with wtrFABP5, the level of p-AKT was 
significantly increased by about 69%, whereas the level of p-AKT was significantly 
reduced by about 21% (Fig 5.2) when treated with dmrFABP5. Results also showed 
that the wtrFABP5 treatment in PC3 cells increased NFκB activity by about 25%, but 
dmrFABP5 reduced the NFκB activity by about 27%. These results suggested that the 
reduction in the level of p-PPARγ produced by dmrFABP5 lead to a significant 
suppression of p-AKT and hence suppressed the activity of NFκB.  These 
suppressions inevitably caused an increased apoptosis of CRPC cells.  Although the 
changes in levels of  activated AKT and NFκB were observed together with the 
change in level of p-PPARγ when PC3 cells were treated with wtrFABP5 or 
dmrFABP5, the molecular mechanisms involved in how FABP5 and FABP5 inhibitors 
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6. Result 4: DmrFABP5 affects expression levels of apoptosis-
related factors- BAX, BCL-2, Caspase-9 and Caspase-3 in 
prostate cancer cells 
6.1. Introduction 
Caspases are a family of protease enzymes which have key influences in protein-
degradation in cells, thus they are essential molecules in the progress of apoptosis, 
pyroptosis and necroptosis (189, 190). BCL-2 is a cytoplasmic protein  and an 
important member of apoptosis- regulating factor family (191) and is a crucial 
suppressor of apoptosis (192, 193). BCL-2 and BAX form a heterodimer, which 
inhibits the promoting function of BAX in apoptosis. Biologically activated AKT can 
act with the down-stream individual members of BCL family of proteins to disrupt 
BCL-2/BAX balance (194, 195). This may lead to a reduced level of Caspase-9 and 
hence suppression of apoptosis (174, 175, 196). Previous studies showed that the 
effect of NFκB activity on apoptosis was achieved through influencing the balance of 
BAX/BCL-2 and its subsequent effect on the levels of Caspase family members, 
particular Caspase-3 (197, 198). Cytochrome C, along with APAF-1 and dATP, then 
bind to procaspase-9 form the “apoptosome”, which is a multi-protein complex. The 
apoptosome hydrolyzes adenosine triphosphate to cleave and activate caspase 9. The 
initiator Caspase-9 then cleaves and activates the executioner Caspases 3, 6, and 7, 
resulting in cell apoptosis  (153).  
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The target of this chapter is to investigate the changes in intrinsic pathway involved in 
apoptosis-suppressing prosess of FABP5 and apoptosis-promoting process of 
dmrFABP5 in PC3 cells. In order to find out whether and how FABP5 affect apoptosis 
through possible PPARγ-downstream pathways, we stimulated the cancer cells with 
both wtrFABP5 and dmrFABP5, and measured the level or the biological activity of 
AKT or NFκB.  We found that both AKT and NFκB responded to treatments of both 
wtrFABP5 and dmrFABP5. 
6.2. Levels of BAX in benign and malignant prostate epithelial cells 
Levels of of BAX expressed in different prostatic epithelial cell lines were measured 
by Western blot and the results were shown in Figure 6.1 (A, B). The level of BAX in 
the benign PNT2 cells was much higher than that in the moderately malignant 22Rv1 
cells, which is higher than that in the highly malignant PC3 cells. When the level in 
the benign PNT2 cells was set at 1, its relative levels in the moderately malignant 
22Rv1 and the highly malignant PC3 cells were 0.49±0.08 and 0.31±0.02, 
respectively (Figure 6.1B); significant reductions by about 51% and 61%, respectively 
(p<0.005, Student’s t-test). 
  
 








Figure 6.1. Levels of BAX in benign and malignant prostate epithelial cells by 
Western blot. A) Western blot analyses of BAX expression in the benign PNT2 cells, 
the malignant 22RV1 and the highly malignant PC3 cells. B) Quantitative assessment 
of the relative levels of BAX by densitometry scanning of the intensities of the bands 
on the blot. The level of BAX in the benign PNT2 cells was set at 1; the levels in 
other cell lines on the same blot were calculated by relating to that of PNT2. Results 
were obtained from three separate measurements (mean ± SE, n=3), the differences 
between the control PNT2 and 22Rv1, PC3 cells were assessed by 2-tailed unpaired 
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6.3. Levels of BCL-2 in benign and malignant prostate epithelial cells 
Levels of BCL-2 was measured by Western blot and the results were shown in Figure 
6.2 (A, B). Based on the intensities of the bands in Figure 6.2A, the level of BCL-2 in 







Figure 6.2. The levels of BCL-2 in benign and malignant prostate epithelial cells by 
Western blot. A) Western blot analyses of BCL-2 expression in the benign PNT2 cells 
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levels of BCL-2 by densitometry scanning of the intensities of the bands on each blot. 
The level of each of BCL-2 in the benign PNT2 cells was set at 1; the levels of other 
cell lines on the same blot were calculated by relating to that of PNT2. Results were 
obtained from three separate measurements (mean ± SE, n=3), the differences 
between the control PNT2 and 22Rv1, PC3 cells were assessed by 2-tailed unpaired 
Student’s t test. 
 
6.4. Levels of cleaved-Caspase-9 in benign and malignant prostate epithelial cells 
Levels of cleaved-Caspase-9 were measured by Western blot and the results were 
shown in Figure 6.3 (A, B). Based on the intensities of bands in Figure 6.3A, level of 
cleaved-Caspase-9 in the benign PNT2 cells was similar to that in the 22Rv1 cells but 
was significantly higher than that in the highly malignant PC3 cells. When the level of 
cleaved-Caspase-9 in PNT2 was set at 1, its relative levels in 22Rv1 and PC3 were 
0.97±0.06 and 0.69±0.03, respectively (Figure 6.3B). While the levels between PNT2 
and 22Rv1 cells were very similar, the cleaved-Caspase-9 level in the highly 
malignant PC3 cells was significantly (p<0.01, Student’s t-test) reduced by 31% when 
compared with that in the benign PNT2 cells. 
  
 







Figure 6.3. The levels of Cleaved-Caspase-9 in benign and malignant prostate cells by 
Western blot. A) Western blot analyses of Cleaved-Caspase-9 expression in the benign 
PNT2 cells and in the malignant 22RV1 and PC3 cells. B) Quantitative assessment of 
the relative levels of cleaved-Caspase-9 by densitometry scanning of the intensities of 
the bands on each blot. The level of each of cleaved-Caspase-9 in the benign PNT2 
cells was set at 1; the levels of other cell lines on the same blot were calculated by 
relating to that of PNT2. Results were obtained from three separate measurements 
(mean ± SE, n=3), the differences between the control PNT2 and 22Rv1, PC3 cells 
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6.5. Levels of cleaved-Caspase-3 in benign and malignant prostate epithelial cells 
Levels of cleaved-Caspase-3 were measured by Western blot and the results were 
shown in Figure 6.4 (A, B). Based on the intensities of the bands in Figure 6.4A, the 
level of the cleaved-Caspase-3 in the benign PNT2 cells was much higher than those 
in 22Rv1 and in PC3 cells. When the level in PNT2 was set at 1, its relative levels in 
22Rv1 and PC3 were 0.54 ± 0.09 and 0.42 ± 0.03, respectively (Figure 6.4B),  











Figure 6.4. The levels of cleaved-Caspase-3 in benign and malignant prostate cells by 
Western blot. A) Western blot analyses of cleaved-Caspase-3 expression in the benign 
PNT2 cells and in the malignant 22RV1 and PC3 cells. B) Quantitative assessment of 
the relative levels of cleaved-Caspase-3 by densitometry scanning of the intensities of 
the bands on each blot. The level of each of cleaved-Caspase-3 in the benign PNT2 
cells was set at 1; the levels of other cell lines on the same blot were calculated by 
relating to that of PNT2. Results were obtained from three separate measurements 
(mean ± SE, n=3), the differences between the control PNT2 and 22Rv1, PC3 cells 





































- 127 - | P a g e  
 
6.6. The effect of dmrFABP5 on levels of BAX expression in PC3 cells 
The effect of dmrFABP5 on the level of BAX in PC3 cells was measured by Western 
blot (Fig 6.5). The androgen-independent cancer cell line PC3 was cultured to 80% 
confluence, the cells were harvested, counted, equal number (1×10
5
) of cells were 
then sub-cultured in triplicates: the control group was treated with PBS, the other 3 
groups were treated with 0.5μM wtrFABP5, 0.5μM dmrFABP5 or combination of 
0.5μM wtrFABP5 and 0.5μM dmrFABP5 for 48 hours, respectively. All the cells were 
harvested and disrupted with a cell lyse buffer. The cell extracts were first subjected to 
SDS-PAGE and then Western blot analysis. An antibody against non-muscle β-actin 
was incubated with each blot to correct possible loading discrepancies. As shown in 
Figure 6.5, treatment with wtrFABP5 reduced the expression of BAX (A). 
Quantitative analysis showed that wtrFABP5 produced a significant decrease 
(p<0.001, Student t-test) in BAX level by about 34% (B). Treatment with dmrFABP5 
promoted the expression of BAX (A). Quantitative analysis showed that significant 
increase (p<0.001, Student t-test) was produced in level of BAX by about 45% (B). 
Treatment with both wtrFABP5 and dmrFABP5 produced no significant difference 
compared with benign group. 
  
 






Figure 6.5. The effect of wtrFABP5 and dmrFABP5 on levels of BAX in PC3 cells. A) 
Western blot analyze of the effects of the treatments with PBS (Control), 0.5µM 
wtrFABP5,  0.5µM dmrFABP5 and combination of 0.5µM wtrFABP5 and 0.5µM 
dmrFABP5 , respectively, on levels of BAX expression. B) Quantitative assessments 
by densitometry scanning of the intensities of the blot bands representing relative 
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at 1. The levels in cells treated with 0.5µM wtrFABP5,  dmrFABP5 and combination 
of 0.5µM wtrFABP5 and 0.5µM dmrFABP5 were calculated, respectively, by relating 
to that in control. Results were obtained from three separate measurements (mean ± 
SE, n=3), the differences between the control and treatments were assessed by 2-tailed 
unpaired Student’s t test. 
 
6.7. The effect of dmrFABP5 on levels of BCL-2 expression in PC3 cells 
The effect of dmrFABP5 on level of BCL-2 expression and in PC3 cells was 
measured by Western blot (Fig 6.6). The androgen-independent cancer cell line PC3 
were cultured to 80% and counted, equal number (1×10
5
) of cells were then sub-
cultured in triplicates: the control group was treated with PBS, the other 3 groups 
were treated with 0.5μM wtrFABP5, 0.5μM dmrFABP5 or combination of 0.5μM 
wtrFABP5 and 0.5μM dmrFABP5 for 48 hours, respectively. All the cells were 
harvested and disrupted with a cell lyse buffer. The cell extracts were first subjected to 
SDS-PAGE and then Western blot analysis. An antibody against non-muscle β-actin 
was incubated with each blot to correct possible loading discrepancies. As shown in 
Figure 6.6, treatment with wtrFABP5 reduced the expression of BCL-2 (A). 
Quantitative analysis showed that wtrFABP5 produced a significant increase (p<0.001, 
Student t-test) in BCL-2 level by about 316% (B). Treatment with dmrFABP5 
promoted the expression of BCL-2 (A). Quantitative analysis showed that significant 
reduction (p<0.05, Student t-test) was produced in level of BCL-2 by about 44% (B). 
Treatment with both wtrFABP5 and dmrFABP5 produced no significant difference 
compared with benign group.  
 









Figure 6.6. The effect of wtrFABP5 and dmrFABP5 on levels of BCL-2 in PC3 cells. 
A) Western blot analyze of the effects of the  treatments with PBS (Control), 0.5µM 
wtrFABP5,  0.5µM dmrFABP5 and combination of 0.5µM wtrFABP5 and 0.5µM 
dmrFABP5 , respectively, on levels of BCL-2 expression. B) Quantitative assessments 
by densitometry scanning of the intensities of the blot bands representing relative 
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set at 1. The levels in cells treated with 0.5µM wtrFABP5,  dmrFABP5 and 
combination of 0.5µM wtrFABP5 and 0.5µM dmrFABP5 were calculated, 
respectively, by relating to that in control. Results were obtained from three separate 
measurements (mean ± SE, n=3), the differences between the control and treatments 
were assessed by 2-tailed unpaired Student’s t test. 
 
6.8. The effect of dmrFABP5 on levels of cleaved-Caspase-9 expression in PC3 
cells 
The effect of dmrFABP5 on the level of cleaved-Caspase-9 expression and in PC3 
cells was measured by Western blot (Fig 6.7). The androgen-independent cancer cell 
line PC3 was cultured to 80% confluent and counted, equal number (1×10
5
) of cells 
were then sub-cultured in triplicates: the control group was treated with PBS, the 
other 3 groups were treated with 0.5μM wtrFABP5, 0.5μM dmrFABP5 or 
combination of 0.5μM wtrFABP5 and 0.5μM dmrFABP5 for 48 hours, respectively. 
All the cells were harvested and disrupted with a cell lyse buffer. The cell extracts 
were first subjected to SDS-PAGE and then Western blot analysis. An antibody 
against non-muscle β-actin was incubated with each blot to correct possible loading 
discrepancies. As shown in Figure 6.7, treatment with wtrFABP5 reduced the 
expression of cleaved-Caspase-9 (A). Quantitative analysis showed that wtrFABP5 
produced a significant reduction (p<0.001, Student t-test) in cleaved-Caspase-9 level 
by about 61% (B). Treatment with dmrFABP5 promoted the expression of cleaved-
Caspase-9 (A). Quantitative analysis showed that significant increase (p<0.001, 
Student t-test) was produced in level of cleaved-Caspase-9 by about 31% (B). 
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Treatment with both wtrFABP5 and dmrFABP5 produced a reduction in levels of 
cleaved-Caspase-9 by about 31%, which was significantly reversed from the effect of 






Figure 6.7. The effect of wtrFABP5 and dmrFABP5 on levels of cleaved-Caspase-9 in 
PC3 cells. A) Western blot analyze of the effects of the treatments with PBS (Control), 
0.5µM wtrFABP5,  0.5µM dmrFABP5 and combination of 0.5µM wtrFABP5 and 
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Quantitative assessments by densitometry scanning of the intensities of the blot bands 
representing relative levels of cleaved-Caspase-9. The level of the control band 
(treated with PBS) in each panel was set at 1. The levels in cells treated with 0.5µM 
wtrFABP5, 0.5µM dmrFABP5 and combination of 0.5µM wtrFABP5 and 0.5µM 
dmrFABP5 were calculated, respectively, by relating to that in control. Results were 
obtained from three separate measurements (mean ± SE, n=3), the differences 
between the control and treatments were assessed by 2-tailed unpaired Student’s t test. 
 
6.9. The effect of dmrFABP5 on levels of cleaved-Caspase-3 expression in PC3 
cells 
The effect of dmrFABP5 on level of cleaved-Capase-3 expression and in PC3 cells 
was measured by Western blot (Fig 6.8). The androgen-independent cancer cell line 
PC3 were cultured to 80% and counted, equal number (1×10
5
) of cells were then sub-
cultured in triplicates: the control group was treated with PBS, the other 3 groups 
were treated with 0.5μM wtrFABP5, 0.5μM dmrFABP5 or combination of 0.5μM 
wtrFABP5 and 0.5μM dmrFABP5 for 48 hours, respectively. All the cells were 
harvested and disrupted with a cell lyse buffer. The cell extracts were first subjected to 
SDS-PAGE and then Western blot analysis. An antibody against non-muscle β-actin 
was incubated with each blot to correct possible loading discrepancies. As shown in 
Figure 6.8, treatment with wtrFABP5 reduced the expression of cleaved-Capase-3 (A). 
Quantitative analysis showed that wtrFABP5 produced a significant decrease 
(p<0.001, Student t-test) in cleaved-Capase-3 level by about 64% (B). Treatment with 
dmrFABP5 promoted the expression of cleaved-Capase-3 (A). Quantitative analysis 
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showed that significant promotion (p<0.05, Student t-test) was produced in level of 
cleaved-Capase-3 by about 23% (B). Treatment with both wtrFABP5 and dmrFABP5 








Figure 6.8. The effect of wtrFABP5 and dmrFABP5 on levels of cleaved-Caspase-3 in 
PC3 cells. A) Western blot analyze of the effects of the  treatments with PBS 
(Control), 0.5µM wtrFABP5,  0.5µM dmrFABP5 and combination of 0.5µM 
wtrFABP5 and 0.5µM dmrFABP5 , respectively, on levels of cleaved-Caspase-3 
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the blot bands representing relative levels of cleaved-Caspase-3. The level of the 
control band (treated with PBS) in each panel was set at 1. The levels in cells treated 
with 0.5µM wtrFABP5,  dmrFABP5 and combination of 0.5µM wtrFABP5 and 
0.5µM dmrFABP5 were calculated, respectively, by relating to that in control. Results 
were obtained from three separate measurements (mean ± SE, n=3), the differences 
between the control and treatments were assessed by 2-tailed unpaired Student’s t test. 
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6.10. Discussion 
Previous studies suggested that the effect of biological activities of both AKT and 
NFκB on apoptosis were achieved through influencing levels of different BCL-2 
family members and hence the balance of the apoptosis-promoting and -suppressing 
elements.   Tipping this balance may result in an activated or an inhibited biological 
activity of the Caspase family, particularly Caspase-9 and Caspase-3 (186, 199-202). 
The heterodimer formed by BCL-2 and BAX can suppress the biological activity of 
BAX (203, 204), thus, the reduction of BAX/BCL-2 ratio to disrupt this balance 
suppressed the cleavages of Caspase-9 and Caspase-3 and resulted in an inhibited 
apoptosis and an enhanced malignant progression (205-207).  
In this study, we first detected the levels of BAX, BCL-2, cleaved-Caspase-9 and 
cleaved-Caspase-3 in benign PNT2 cells and in the malignant 22Rv1 and PC3 cells. 
As showed in the results, the level of BAX (Fig 6.1) and cleaved-Caspase-3 (Fig 6.4) 
in the benign PNT2 cells was much higher than that in the moderately malignant 
22Rv1 cells, which is higher than that in the highly malignant PC3 cells. Whereas the 
level of cleaved-Caspase-9 in the benign PNT2 cells was similar to that in the 22Rv1 
cells but was significantly higher than that in the highly malignant PC3 cells (Fig 6.3). 
The levels of BCL-2 were similar amongst these cell lines (Fig 6.2). These results 
suggested that in the malignant prostate cancer cells, the cleaved caspases is less 
active than that in the benign cells indicating a suppressed apoptosis is related to the 
increased level of FABP5 expression.  
It was shown that PC3 cells treated with wtrFABP5 greatly reduced the level of BAX 
by about 34% (Fig 6.5), and greatly increased the level of BCL-2 by about 316% (Fig 
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6.6). In contrast, the treatment with dmrFABP5 significantly increased the level of 
BAX by about 45% (Fig 6.5) but reduced the level of BCL-2 by about 44% (Fig 6.6). 
Whereas the treatment with both wtrFABP5 and dmrFABP5 showed no significant 
difference on levels of BAX and BCL-2 in PC3 cells. This result showed that changes 
in both BAX and BCL-2 levels obtained by wtrFABP5 were completely reversed (not 
significantly different from control) with the treatment with dmrFABP5 in PC3 cells.  
Similarly, Changes in both BAX and BCL-2 levels obtained by dmrFABP5 were 
completely reversed with the treatment with wtrFABP5. Further investigation showed 
that wtrFABP5 produced significant reduction in levels of cleaved-Caspase-9 by 
about 61%, whereas dmrFABP5 promoted the levels of cleaved-Caspase-9 by about 
31%. Treatment with both wtrFABP5 and dmrFABP5 have neutralised about 51% of 
the effect produced by wtrFABP5, but this level was still significantly lower than that 
in the control by about 31%.  Thus, the promoting effect of dmrFABP5 in level of 
cleaved-Caspase-9 was not strong enough to completely reverse that suppressive 
effect of wtrFABP5 (Fig 6.7), indicating that a more complicated mechanism maybe 
involved in the cleavage of Caspase-9, apart from the effect of FABP5. Thus, further 
investigation is needed to find out what other factors are involved in suppressing the 
biological activity of Caspase-9. The results in this work also showed that wtrFABP5 
produced significant reduction in levels of cleaved-Caspase-3 by about 64%, whereas 
dmrFABP5 promoted the levels of cleaved-Caspase-3 by about 23% (Fig 6.8). 
Changes in cleaved-Caspase-3 level obtained by wtrFABP5 was completely reversed 
with the treatment with dmrFABP5 in PC3 cells.  Similarly, changes in cleaved-
Caspase-3 level obtained by dmrFABP5 was completely reversed with the treatment 
with wtrFABP5. 
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7. General Discussion, conclusion and future work 
Prostate cancer is the most commonly diagnosed male cancer and the second leading 
cancer-related death in male in the rich western countries (4). Since Higgins and 
associates discovered that the growth and expansion of prostate cancer cells are 
dependent on the stimulations of male hormone supplied through peripheral blood 
circulation (208), androgen deprivation by physical or pharmaceutical castration or 
suppressing the biological activity of AR has been the primary treatment for patients 
with prostate cancer over the past 50 years (209). Despite the initial effectiveness, 
prostate cancer usually come back in about two years with a more aggressive 
hormone-independent phenotype, called CRPC. CRPC does not effectively sensitive 
to ADT anymore because the growth and progression of CRPC cells are no longer 
dependent on circulating hormones (210). The conversion of androgen-dependent 
cancer cells to androgen-independent CRPC cells is a fundamental change, and the 
molecular mechanism involved in this change is not fully understood (211). To 
develop new therapeutic strategies, it is necessary to conduct further investigations on 
molecular mechanisms involved in the malignant progression of prostate cancer. Our 
previous studies suggest that AR may be unrelated to the malignant progression of 
CRPC. Instead of AR-mediated signaling pathway, FABP5-PPARγ-VEGF axis 
possibly play a more effective role in CRPC (123, 135). Fatty acids were 
demonstrated to function in cellular building and initiation of signaling pathway in 
cancer cells and have important influences in tumourigenisity and metastasis of 
cancer cells (212, 213). High level of FABP5 in prostate cancer has been suspected as 
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a promoter for cell growth and metastasis (214). It has been proved that FABP5 
delivers fatty acids from intracellular and extracellular sources into cells and enhance 
the activity of their nuclear receptor PPARγ in prostate cancer cells (123, 135). The 
siRNA knockdown of FABP5 shown an effective inhibition of growth in highly 
malignant prostate cancer cells in vivo (134), however, the siRNA was unstable and 
loss their function in a short time. Thus, targeting FABP5 biological function could be 
considered a new way for CRPC treatment. Our previous studies demonstrated that 
with the treatment of both chemically-synthesized inhibitor (SB-FI-26) and a bio-
inhibitor (dmrFABP5) for FABP5, its biological activity was suppressed and hence 
the tumour growth and metastasis were significantly reduced (147). Our previous 
studies also demonstrated that FABP5-related signal transduction pathway plays an 
crucial role in promoting malignant progression of prostate cancer cells and it is 
possible for FABP5 to promote tumorigenicity and metastasis through the inhibition 
of cellular apoptosis (107, 129, 131). To study the possible molecular mechanisms 
underlying the tumour-suppressing effect of the FABP5 inhibitors, here for the first 
time, we conducted a systematic assessment on whether promoting cellar apoptosis is 
part of the mechanisms for these inhibitors to suppress the malignant progression of 
the CRPC cells. The results in this study can be summarized as following: 
1- FABP5 inhibitors promoted the apoptosis in both moderately malignant 
androgen sensitive 22Rv1 cells and the highly malignant androgen independent 
PC3 cells.  
2- The increased apoptosis caused by dmrFABP5 is possibly caused by the 
reduction of p-PPARγ level. 
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3- The increased level of p-PPARγ produced by wtrFABP5 treatment lead to a 
significant promotion of p-AKT and hence promote the activity of NFκB, 
whereas the reduced level of p-PPARγ produced by dmrFABP5 lead to a 
significant suppression of p-AKT and hence suppressed the activity of NFκB. 
4- Pro-apoptotic BAX and cleaved-Caspases in malignant prostate cancer cells 
were much less active than those in benign PNT2 cells but the anti-apoptotic 
BCL-2 remained a similar levels amongst the benign and the malignant cells. 
5- WtrFABP5 suppressed pro-apoptotic BAX level and increased the anti-
apoptotic BCL-2 level, which led to a significant reduction in BAX/BCL-2 ratio 
in PC3 cells. Wheras dmrFABP5 promoted pro-apoptotic BAX level and 
suppressed the anti-apoptotic BCL-2 level, which led to a significant increasing 
in BAX/BCL-2 ratio in PC3 cells. 
6- WtrFABP5 produced significant reduction in the level of cleaved-Caspase-9 and 
cleaved-Caspase-3, whereas dmrFABP5 promoted the level of cleaved-Caspase-
9 and cleaved-Caspase-3 in PC3 cells. 
7.1 FABP5 and FABP5 inhibitors implicated apoptosis in prostate cancer cells. 
In order to investigate the possible effect of FABP5 on cell apoptosis, the moderately 
malignant androgen sensitive 22Rv1 cells and the highly malignant androgen 
independent PC3 cells were treated with wtrFABP5 first and then treated with two 
FABP5 inhibitors: the chemical inhibitor SB-FI-26 and the bio-inhibitor dmrFABP5. 
Before treatment, we found that the percentage of apoptotic cells in 22Rv1 was 
significantly higher than that in PC3 (Fig. 3.2). Considering that fact that the level of 
FABP5 in 22Rv1 is lower and the malignancy in 22Rv1 is lower than those in PC3, 
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the result in this work suggested that the increased level of FABP5 is closely 
associated with the reduced level of the percentage of cells undergoing apoptosis. 
When treated with wtrFABP5, significant suppression of apoptosis were found in both 
22Rv1 and PC3 cells (Fig 3.2). This result plus our previous work suggested that the 
increased level of FABP5 may play a suppressive role in apoptosis and this role may 
contribute, at least partially, to the caner-promoting activity of FABP5 in prostate 
cancer.  As showed in figure 3.4, when treated with 150μM SB-FI-26, more 22Rv1 
and PC3 cells underwent apoptosis. Whereas when treated with 0.5µM dmrFABP5, 
more 22Rv1 and PC3 cells underwent apoptosis (Fig 3.6). These results showed that 
completely opposite to wtrFABP5, the role of the inhibitors SB-FI-26 or dmrFABP5 
are promoting apoptosis. DmrFABP5 had a better promotion effect (about 1.5 fold 
promotion) in apoptosis of the highly malignant PC3 cells compared with SB-FI-26 
(about 0.7 fold promotion). Thus, it is possible that the FABP5 inhibitors suppressed 
the malignant progression of prostate cancer cells, at least partly, by promoting the 
apoptosis of cancer cells. These results provided a theoretical basis for possible 
therapeutic strategies for prostate cancer, especially CRPC, by inducing apoptosis 
obtained by FABP5 inhibitors.  
7.2 PPARγ was correlated with modulating changes in  apoptosis caused by 
wtrFABP5 and dmrFABP5 in prostate cancer cells.  
FABP5 can transport a large amount of fatty acids into prostate cancer cells (215). 
While most of these fatty acids are used as alternative energy sources, the excessive 
amount of fatty acids were transported into nucleus, as signaling molecules, to 
stimulate the nuclear receptor PPARγ (216). PPARγ is located in nuclear membrane,  
it is highly expressed in adipose tissue and plays an important role to regulate 
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adiposity and insulin sensitivity (159). Our Previous studies demonstrated that the 
FABP5-PPARγ-VEGF influenced malignant progression and cellular apoptosis of 
CRPC (107, 123, 135). In this work, we detected the change in levels of PPARγ and 
p-PPARγ in untreated prostate cancer cells and in highly malignant PC3 cells when 
treated with wtrFABP5 or dmrFABP5. Results showed that the total PPARγ levels in 
PC3 cells were higher than that in 22Rv1 cells and lower than that in the benign PNT2 
cells, (Fig 4.1); and the levels of PPARγ were not significantly different in PC3 cells 
when treated with wtrFABP5 or dmrFABP5 (Fig 4.2). However, the p-PPARγ levels 
in 22Rv1 and PC3 cells were significantly higher than that in PNT2 (Fig 4.1); the 
level of p-PPARγ was significantly increased in highly malignant PC3 cells by 39% 
when treated with wtrFABP5, whereas treatment with dmrFABP5 significantly 
reduced the level of p-PPARγ in PC3 cells (Fig 4.3). These results showed that the 
total level of PPARγ did not respond to the treatments with either wtrFABP5 or 
dmrFABP5, but the level of p-PPARγ or the biologically active PPARγ was 
significantly increased when treated with wtrFABP5. Whereas when treated with 
dmrFAB5, the level of p-PPARγ was significantly reduced, which suggested that 
dmrFABP5 played a completely opposite role to wtrFABP5 and suppressed the 
activation of PPARγ. Thus, the increased apoptosis caused by dmrFABP5 shown in 
previous results is possibly caused by the reduction of p-PPARγ level; PPARγ may 
play a central role in modulating changes related to apoptosis. 
7.3 AKT and NFκB pathways were correlated with modulating changes in  
apoptosis caused by wtrFABP5 and dmrFABP5 in prostate cancer cells.  
To study the molecular mechanism of how p-PPARγ affected apoptosis, we first 
investigated the change in prostate cancer cells on the PI3K-AKT- signal pathway, 
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which controls cell survival and apoptosis, and which is influenced by the changes of  
the p-PPARγ level. The activation of AKT pathway promotes cell survival and 
reduces cellular apoptosis in different types of cancer cells including prostate cancer 
(164-166). It was reported that the way that AKT affected apoptosis was through 
regulating the individual protein members of the BCL-2 family and changing the 
balance of cancer- promotive- or suppressive- forces, hence triggering the change of 
caspase-9 (174-176). As AKT also affects the activation of NFκB by influencing the 
upstream factor p65 subunit of the NFκB pathway (180, 181), and the activation of  
NFκB can regulate the expression of downstream genes involved in cell growth and 
apoptosis (183-185), we then detected the level of activation of NFκB in prostate 
cancer cells. Result showed that the level of total AKT in the benign PNT2 cells were 
much higher than that in the moderately malignant 22Rv1 and in the highly malignant 
PC3 cells (Figure 5.1). Whereas compared with the level of the expression of p-AKT 
in PNT-2 cells, the level was greatly increased in 22Rv1 cells and PC3 cells (Fig. 5.1). 
These results suggested that the levels of activated AKT were increased in the 
moderately malignant 22Rv1 cells and further greatly increased in the highly 
malignant PC3 cells. Another result showed that when PC3 cells were treated with 
wtrFABP5, the level of p-AKT was significantly increased, the level of p-AKT was 
significantly reduced (Fig. 5.2) when treated with dmrFABP5. Results also showed 
that the wtrFABP5 treatment in PC3 cells increased NFκB activity, but dmrFABP5 
reduced the NFκB activity when compared with the PC3 control (Fig. 5.3). These 
results proved that the increase in level of p-PPARγ produced by wtrFABP5 lead to a 
significant promotion of p-AKT and hence promote the activity of NFκB and cell 
survival. Whereas the reduction in level of p-PPARγ produced by dmrFABP5 lead to a 
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significant suppression of p-AKT and hence suppressed the activity of NFκB.  These 
suppressions maybe inevitably caused an increased apoptosis of CRPC cells. 
7.4 Highly malignant prostate cancer cells expressed lower level of BAX 
compared with benign cells.   
Previous studies proved that the effect of biological activities of both AKT and NFκB 
on apoptosis were achieved through influencing levels of different BCL-2 family 
members and hence disrupting the balance of the apoptosis-promoting and -
suppressing elements (217-219). Tipping this balance may result in an activated or an 
inhibited biological activities of the Caspase family, particularly Caspase-9 and 
Caspase-3 (186, 199-201). Since AKT and NFκB activities were suppressed through 
p-PPARγ with the treatment of dmrFABP5, detailed investigation on levels of the 
related apoptosis-inducer and apoptosis-suppressor may help to understand the 
mechanisms involved in how p-PPARγ influencing cellular apoptosis. Results showed 
that the level of pro-apoptotic BAX (Fig 6.1) in the benign PNT2 cells was much 
higher than that in the moderately malignant 22Rv1 cells, which is higher than that in 
the highly malignant PC3 cells. The levels of cleaved-Caspase-3 (Fig 6.4) in the 
benign PNT2 cells was much higher than that in 22Rv1 cells, which is higher than 
that in PC3 cells. Whereas the level of cleaved-Caspase-9 in the benign PNT2 cells 
was similar to that in the 22Rv1 cells but was significantly higher than that in the 
highly malignant PC3 cells (Fig 6.3). The levels of anti-apoptotic BCL-2 were similar 
amongst these cell lines (Fig 6.2). These results suggested that in the malignant 
prostate cancer cells, pro-apoptotic BAX and cleaved-Caspases were much less active 
than those in benign PNT2 cells but the anti-apoptotic BCL-2 remained a similar 
levels amongst the benign and the malignant cells, which indicated that apoptosis was 
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suppressed in the cancer cells but it is very active in the benign cells. In another word, 
in the benign PNT2 cells which express low or undetected level of FABP5, apoptosis 
mechanism is active and the programmed cell death occurred normally. However, in 
the CRPC cells 22Rv1 and PC3 which express an increased level of FABP5,  the 
opposite to the PNT2 cells was observed and the apoptotic mechanism is highly 
suppressed and much less cells undergoing apoptosis, and thus as a result of the 
reduced apoptosis, the malignant progression is obtained and enhanced.   
7.5 WtrFABP5 and dmrFABP5 affected the levels of BAX, BCL-2, cleaved-
Caspase-9 and cleaved-Caspase-3 in prostate cancer cells. 
When PC3 cells were treated with wtrFABP5, the level of BAX was reduced (Fig 6.5), 
but the level of BCL-2 was greatly increased (Fig 6.6). On the contrary, when PC3 
cells were treated with dmrFABP5, the level of BAX was significantly increased (Fig 
6.5) but the level of BCL-2 was greatly reduced by (Fig 6.6). Whereas the treatment 
with both wtrFABP5 and dmrFABP5 showed no significant difference on levels of 
BAX and BCL-2 in PC3 cells (Fig 6.5, 6.6). These results provided a direct evidence 
that wtrFABP5 suppressed pro-apoptotic BAX and increased the anti-apoptotic BCL-
2, which led to a significant reduction in BAX/BCL-2 ratio. These results also showed 
that the apoptosis-suppressive effect exerted by wtrFABP5 was reversed completely 
by the treatment of dmrFABP5. Similarly, the effect in both pro-apoptotic BAX and 
anti-apoptotic BCL-2 levels produced by dmrFABP5 were completely reversed with 
the treatment with wtrFABP5. Further studies also showed that wtrFABP5 produced 
significant reduction in the level of cleaved-Caspase-9, whereas dmrFABP5 promoted 
the level of cleaved-Caspase-9 in PC3 cells. Treatment with both wtrFABP5 and 
dmrFABP5 have neutralised effect produced by wtrFABP5, but this level was still 
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significantly lower than that in the control by about 30%.  Therefore, the promoting 
effect of dmrFABP5 on level of cleaved-Caspase-9 was not strong enough to 
completely reverse that suppressive effect of wtrFABP5 (Fig 6.7), indicating that a 
more complicated mechanisms or other unknown factors maybe involved in the 
cleavage of Caspase-9, apart from the effect of FABP5. Further studies is needed to 
investigate all pathways and factors that are involved in suppressing the biological 
activity of Caspase-9 when the cellular apoptosis is influenced by FABP5 inhibitor. 
Further investigation in this work showed that wtrFABP5 produced significant 
reduction in levels of cleaved-Caspase-3, whereas dmrFABP5 promoted the levels of 
cleaved-Caspase-3 (Fig 6.8). These changes in level of cleaved-Caspase-3 obtained by 
wtrFABP5 was completely reversed with the treatment with dmrFABP5 in PC3 cells. 
Similarly, Changes in cleaved-Caspase-3 level obtained by dmrFABP5 was 
completely reversed with the treatment with wtrFABP5. Thus, wtrFABP5 and 
dmrFABP5 played opposite roles inside cancer cells, and affected the malignant 
progression through exerting opposite influences on apoptosis. 
7.6 Possible in vivo detection on apoptosis and potential clinical implementation 
of FABP5 inhibitors in prostate cancer cells 
Previously, it is reported that suppression of the biological function of FABP5 by 
inhibitors inhibited the migration and invasion of prostate cancer cells in vitro and in 
vivo. These results suggest that both FABP5 inhibitors are potent inhibitors on 
malignant progression of CRPC cells in vitro and in vivo and the suppression effect of 
the bio-inhibitor dmrFABP5 is much stronger than that of the chemically synthesised 
SB-FI-26 (155). In this work, the in vitro results showed the suppression  of the 
FABP5 by inhibitors promoted the apoptosis of prostate cancer cells. Further 
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detection of the effect of FABP5 inhibitors on apoptosis in prostate cancer should be 
done in the future. 
Currently, ADT is a main therapy against prostate cancer. Since the growth of prostate 
cancer is dependent on androgen at early stages of treatment, blockage of androgen is 
an effective therapy against prostate cancer. However, ADT can not fully cure prostate 
cancer and prolonged therapy usually make conversion to CRPC. Therefore, Previous 
pathological studies have shown that FABP5 overexpression is strongly associated 
with prostate cancer progression and metastasis (155). Some studies indicated that 
inhibition of the biological functions of FABP5 could be an effective treatment to 
suppress multiple steps that are important in tumour progression and metastasis in 
nude mice (155). The results on prostate cancer proliferation, metastasis and apoptosis 
obtained from targeting FABP5 biological function provided clues for a new way to 
treat patients with CRPC, and  they also provided a theoretical basis for resolving 
possible problems raised from the treatment by targeting PPARγ or VEGF (123). 
7.7 Conclusion 
In conclusion, as shown by the schematic illustration in Figure 7.1, by transporting 
excessive amount of fatty acids to stimulate PPARγ, the increased level of FABP5 up-
regulated the level of p-PPARγ, which directly or indirectly promoted both level of p-
AKT and the activity of NFκB in prostate cancer cells.  The up-regulation of p-AKT 
and activated NFκB led to the reduction of BAX and the subsequent change of the 
BAX/BCL-2 ratio, suppressed the cleavages of Caspase-9 and Caspase-3 and thus 
inhibited cellular apoptosis and promoted malignant progression. In contrast, the 
FABP5 inhibitors SB-FI-26 (147) and dmrFABP5 inhibited the level of p-PPARγ by 
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cessation of fatty acid stimulation through competitively binding to fatty acids (SB-
FI-26) or a possible obstruction of fatty acid delivery (dmrFABP5). Then the reduced 
level of p-PPARγ triggered the suppression in p-AKT and activity of NFκB and an 
increase of the ratio of BAX/BCL-2, which increased the levels of cleaved-Caspase-9 
and cleaved-Caspase-3 and hence promoted apoptosis and inhibited the malignant 
progression of the cancer cells.  
 
 
Figure 7.1 Schematic illustration of the possible FABP5-related signaling pathway 
leading to apoptosis-inhibition and the apoptosis-promoting effect of dmrFABP5 in 
prostate cancer cells. In untreated prostatic cancer, high level of FABP5 transports a 
large amount of fatty acids into cells and the excessive amount of fatty acids activate 
nuclear fatty acid receptor PPARγ by phosphorylation. The p-PPARγ binds to DNA at 
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peroxisome proliferator response elements (PPREs) and activate the downstream 
regulatory factors, which may then activate AKT directly or indirectly. The p-AKT 
can suppress apoptosis by promoting the activity of NF-kB, which can influence the 
mitochondrial BAX/BCL-2 balance in the way favoring apoptosis-inhibition. The 
activation of AKT can also lead to a increased cleaved-Caspase-9 level. DmrFABP5 is 
incapable of binding to fatty acids, but it has a very similar structure to wtrFABP5. 
DmrFABP5 may bind to PPARγ in the same way as wtrFABP5 to competitively 
occupy the space without carrying fatty acid, thus dmrFABP5 prevent wtrFABP5 
from contacting PPARγ to deliver the fatty acids. This disruption of the fatty acid 
transportation and stimulation of PPARγ may lead to a cessation of PPARγ activation. 
The reduced level of p-PPARγ can lead to an increased apoptosis of the cancer cells 
either by the reduction of the level of p-AKT, which causes the cleavage of Caspase-3 
or by the suppression of the NF-kB activity, which can influence the BAX/BCL2 
balance and the cleavage of Caspase-3 in the direction favoring apoptosis-promotion. 
7.8 Future work 
In this work, we detected the changes in apoptosis under the treatments of  FABP5 
inhibitors in prostate cancer cells and studied some possible mechanisms involved in 
the apoptosis promotion under the suppression of FABP5 biological function in CRPC. 
The bio-inhibitor dmrFABP5 suppresses the biological function of FABP5 and works 
by blocking the fatty-acid stimulation of PPARγ to prevent it from activating the 
down-stream regulatory cancer-promoting and surviving genes. Since the exact 
pathway of fatty acid delivery to PPARγ is not clear, how dmrFABP5 inhibits PPARγ 
is not fully understood. Furthermore, the exact mechanisms of  how suppressed p-
PPARγ affect AKT activation and the following pathways involved in this apoptosis 
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promoting effect are not fully studied. Further investigation is needed to understand 
the detailed molecular mechanisms involved in the suppressive effect of dmrFABP5 
on PPARγ activation and the clear apoptosis related (intrinsic and extrinsic) pathways 
involved in FABP5-apoptosis promoting effect. In addition, further preclinical work 
on toxicity and pharmacokinetics studies are needed before the true clinical 
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AccuWeigh, WA, USA  
 
Portable Lab Scale 
 




BD) FACSCanto , UK 
 
FACSCanto II Flow Cytometer  
 
 















Becton Dikinson, USA  
 
Falcon 2059 tube  
 
 








BioTek, USA  
 
Multiskan MS (plate reader) 
 
Borolabs, Basingstoke, UK  
 
CO2 incubator Model TC2323 
 




Generier bio-one, UK 
  
Tissue culture pipettes (5-50 ml)  Universal tube 
 
 





Leica, Germany  
 
Superior Adhesive slide  
 
 





Merck Millipore, UK  
 
Immobilon, Transfer membrane  
 
 
Merck Millipore, UK  
 
D-Tube dialyzer  
 






Nalgene, UK  
 




New Brunswick Scientific, USA  
 
CO2 Shaking incubator 
 
 
Nunc, Denmark  
 
Cell culture filter cap flasks  
 





QIAGEN, Crawley, UK  
 
Qiagen tip  
 
QIA Shredder spin column 
 
 




























Whatman, England, UK  
 
Whatman filter paper 
 
 














BDH, England, UK 
Ampicillin 
 
Invitrogen, CA, USA 
Agarose 
 




DH5α E. coli bacteria 
 
Invitrogen, CA, USA 
DNA marker III 
 
Roche, England, UK 
























Ligation enzyme buffer 
 




Magnesium sulphate Sigma, USA 
 


















QIAGEN Ni-NTA Fast Start Kit 
 
QIAGEN, CA, USA 
QIAGEN Plasmid mini-preparation kit 
 
QIAGEN, CA, USA 
Restriction enzyme buffers 
 
New England BioLabs 
 








T4 DNA ligase 
 




Wizard DNA Clean-Up System 
 
Promega, WI, USA 
Xylene 
 
GENTA, Tockwith, UK 
Yeast extract 
 
Fisher scientific, Loughborough, UK 
  
8.2.2. Reagents for cell culture 
 
DMSO Sigma, USA 
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Fetal calf serum 
 






Lonza, Belgium  
Phosphate buffered saline 
 
Gibco, Invitrogen, Paisley, UK 
RPMI 1640 
 
Gibco, Invitrogen, Paisley, UK 
Trypsin 
 
Gibco, Invitrogen, Paisley, UK 
Versene 
 
Gibco, Invitrogen, Paisley, UK 
 
 
8.2.3. Reagents for western blot 
 
 





Stain-Free™  Precast Gels 
 







Commassie brilliant blue 
 
Bio-Rad GmbH, Munchen, Germany 
Immobilon ECL Ultra Western HRP 
substrate 
 















Merck Millipore, UK 









2×sample loading buffer 
 
Bio-Rad GmbH, Munchen, Germany 
25×running buffer 
 
Bio-Rad GmbH, Munchen, Germany 
 
8.2.4. Reagents for flow cytometry 
 
Annexin V-FITC Apoptosis 
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8.2.5. Reagents for cell nuclear extraction 
 
Nuclear extraction kit 
 
Abcam, UK 
DTT Sigma, USA 
 
8.2.6. Reagents for  NFκB transcription factor assay 
 









8.3.1. Buffers for western blot 
 
Transfer buffer (pH 8.3)  
 
Glycine 14.4g (192mM)  
 
Tris base 3.03g (25mM)  
 
Methanol 20% (v/v)  
 
Fill dH2O to 1Lit  
 
pH is adjusted with HCl and NaOH 
 
10× TBS buffer (pH 7.6)  
Sodium chloride 87.66g (1500mM)  
 
Tris base 60.58g (500mM)  
 
Fill dH2O to 1 Lit  
 
pH is adjusted with HCl and NaOH 
 
1×TBS-Tween 1%  
 
10× TBS buffer 100ml  
 
Tween-20 1ml  
 
Fill dH2O to 1 Lit 
 
TBS-T-milk 5%  
 
Dried skimmed milk 5g  
 
1×TBS-T buffer 100ml 
 




8.3.2. Buffers for cell culture 
 
Routine cell culture medium  
 
RPMI medium 1640 500ml  
 
Fetal calf serum (FCS) 10% (v/v)  
 
Penicillin-Streptomycin (5000 U/ml) 5ml  
 
L-Glutamine (20mM) 5ml  
 
 
Trypsin/Versene solution  (2.5%) 




Freezing medium  
 
Routine cell culture medium 92.5% (v/v)  
 




PBS tablet  1 
 











8.3.3. Buffers for molecular biology 
 
LB medium  
 
LB broth 20g  
 




LB agar  
 
LB agar 35g  
 




RF1 buffer (pH 5.8)  
 
KCl 7.456g (100mM)  
 
MgCl2.4H2O 9.9g (50mM)  
 
CaCl2 1.5g (10mM)  
 
K-acetate 2.94g (30mM)  
 
Glycerol (v/v) 150ml (15%)  
 
Fill dH2O to 1 Litre  
 
pH was adjusted  
Sterilized by filtration 
 
RF2 buffer (pH 6.8)  
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MOPS 2.1g (10mM)  
 
CaCl2 11g (75mM)  
 
KCl 0.745g (10mM)  
 
Glycerol (v/v) 150ml (15%)  
 
dH2O up to 1 Lit  
 
pH was adjusted 
Sterilized by autoclave 
 
Glucose 20%  
 
Glucose 20g  
 
dH2O 10ml  
 
Sterilized by filtration 
 
SOB medium (pH 7)  
 
NaCl 0.5g  
 
Tryptone 20g  
 
Yeast extracts 5g  
 
KCl 0.186g  
 
dH2O up to 1 Lit  
 
pH was adjusted  
Sterilized by autoclave 
 
SOC medium  
 
SOB medium 4.85ml  
 
Mg2+ salt solution (2M) 50μl  
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Glucose 20% 150μl 
 
Stock medium for bacteria  
 
Glycerol 5ml  
 
LB medium 4ml  
 
Bacteria culture 3ml 
 
100mM IPTG  
 
IPTG 238mg  
 




10× TBE stock solution  
 
Boric acid 55g (890mM)  
 
Tris base 108g (890mM)  
 
EDTA 0.5M, pH 8 40ml (20mM)  
 
Fill dH2O to 1 Lit  
 
pH was adjusted  
Sterilized by autoclave 
 
6×DNA loading buffer  
 
Bromophenol blue 0.5% 0.5ml  
 
Xylene cyanol FF 0.5ml  
 
Glycerol in sterile dH2O (60%) 1ml 
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8.3.4. Cell line authentication  
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